Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 7060. Отображено 100.
02-02-2012 дата публикации

Synthesis of enone intermediate

Номер: US20120029199A1
Принадлежит: Harvard College

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides a more efficient route for preparing the enone intermediate.

Подробнее
01-03-2012 дата публикации

Azafluorene derivative and organic light-emitting device using the derivative

Номер: US20120049176A1
Принадлежит: Canon Inc

A novel azafluorene derivative and an organic light-emitting device having the derivative are provided. The organic light-emitting device includes a pair of electrodes composed of an anode and a cathode one of which is a transparent or semi-transparent electrode, and an organic compound layer interposed between the pair of electrodes. The organic compound layer contains the azafluorene derivative represented by the following general formula (I):

Подробнее
03-05-2012 дата публикации

Compounds for the treatment of multi-drug resistant bacterial infections

Номер: US20120108577A1
Принадлежит: AstraZeneca AB

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm-blooded animals such as humans.

Подробнее
30-08-2012 дата публикации

Novel organic electroluminescent compounds and organic electroluminescent device using the same

Номер: US20120217485A1

Provided are novel organic electroluminescent compounds and organic electroluminescent devices using the same. Since the organic electroluminescent compound exhibits good luminous efficiency and excellent life property compared to the existing material, it may be used to manufacture OLED devices having superior operation life and consuming less power due to improved power efficiency.

Подробнее
04-10-2012 дата публикации

Pyridinecarboxamides, useful-plant-protecting composition comprising them and processes for their preparation and their use

Номер: US20120252670A1
Принадлежит: Individual

Compounds of the formula (I), or salts thereof, in which R 1 to R 4 are as defined in formula (I) of claim 1 are suitable as useful-plant-protecting agents for reducing or preventing harmful effects of agrochemicals on the useful plants and their method of preparation are described.

Подробнее
18-10-2012 дата публикации

Composition and method for controlling arthropod pests

Номер: US20120264750A1
Автор: Junko Otsuki
Принадлежит: Sumitomo Chemical Co Ltd

The present invention provides: an arthropod pests control composition comprising, as active ingredients, a condensed heterocyclic compound and a diamide compound; a method for controlling arthropod pests which comprises applying effective amounts of a condensed heterocyclic compound and a diamide compound to the arthropod pests or a locus where the arthropod pests inhabit; and so on.

Подробнее
01-11-2012 дата публикации

Process for the preparation of crystalline aprepitant having form i content

Номер: US20120277426A1
Принадлежит: Ranbaxy Laboratories Ltd

The present invention provides a process for preparation of crystalline aprepitant having not more than 15% by weight of Form I content which comprises, a) dissolving aprepitant in a suitable solvent to obtain a solution, b) cooling the solution to 10-15° C., c) optionally seeding the solution with aprepitant Form I crystals, d) adding an anti-solvent to the solution, and e) isolating crystalline aprepitant having not more than 15% by weight of Form I content.

Подробнее
15-11-2012 дата публикации

Novel compounds with high therapeutic index

Номер: US20120289471A1
Автор: V. Ravi Chandran
Принадлежит: Signature R&D Holdings LLC

The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

Подробнее
03-01-2013 дата публикации

Cyclic amine bace-1 inhibitors having a benzamide substituent

Номер: US20130004518A1
Принадлежит: Merck Sharp and Dohme LLC

Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is R is —C(O)—N(R 27 )(R 28 ) or and the remaining variables are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are pharmaceutical compositions and methods of treating cognitive or neurodegenerative diseases comprising the compounds of formula I in combination with a β-secretase inhibitor other than those of formula I, an HMG-CoA reductase inhibitor, a gamma-secretase inhibitor, a non-steroidal anti-inflammatory agent, an N-methyl-D-aspartate receptor antagonist, a cholinesterase inhibitor or an anti-amyloid antibody.

Подробнее
28-02-2013 дата публикации

Novel cationic 4- aminoindoles, dye composition comprising a cationic 4-aminoindole, processes therefor and uses thereof

Номер: US20130048007A1
Автор: Aziz Fadli
Принадлежит: LOreal SA

The present invention relates to a cationic aminopyridine of general formula (I), acid-addition salts thereof and solvates thereof: in which: R 1 is a linear or branched, saturated C 1 -C 20 alkyl radical, substituted and/or interrupted with a cationic radical. The present invention is also directed towards a process for synthesizing this cationic aminopyridine, compositions, uses, hair dyeing processes and devices using this cationic aminopyridine.

Подробнее
21-03-2013 дата публикации

Cyclothiocarbamate Derivatives as Progesterone Receptor Modulators

Номер: US20130072480A1
Принадлежит: WYETH LLC

Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure: 1. A method of contraception , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female of child bearing age.2. A method for providing hormone replacement therapy , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a mammalian subject3. A method of treating fibroids , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female patient.4. A method of treating endometriosis , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female patient.5. A method of treating dysfunctional bleeding , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female patient.6. A method of treating uterine leiomyomata , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female patient.7. A method of treating polycystic ovary syndrome , said method comprising delivering 5-(4 ,4-Dimethyl-2-thioxo-1 ,4-dihydro-2H-3 ,1-benzoxazin-6-yl)-1-methyl-1H-pyrrole-2-carbonitrile or a pharmaceutically acceptable salt thereof to a female patient.8. ...

Подробнее
21-03-2013 дата публикации

PYRIMIDINE CYCLOHEXYL GLUCOCORTICOID RECEPTOR MODULATORS

Номер: US20130072486A1
Принадлежит: Corcept Therapeutics, Inc.

The present invention provides a class of pyrimidinedione cyclohexyl compounds and methods of using these compounds as glucocorticoid receptor modulators. 5. The compound of claim 1 , wherein Ris selected from the group consisting of aryl and heteroaryl.6. The compound of claim 1 , wherein Ris selected from the group consisting of phenyl claim 1 , pyridyl claim 1 , pyrimidine claim 1 , and thiazole.7. The compound of claim 1 , wherein each Ris independently selected from the group consisting of H claim 1 , Calkyl claim 1 , Calkoxy claim 1 , halogen claim 1 , Chaloalkyl claim 1 , —NRR claim 1 , and —SOR.8. The compound of claim 1 , wherein each Ris Chaloalkyl.9. The compound of claim 1 , wherein each Ris independently selected from the group consisting of H claim 1 , Me claim 1 , Et claim 1 , —OMe claim 1 , F claim 1 , Cl claim 1 , —CF claim 1 , —NMe claim 1 , and —SOMe.10. The compound of claim 1 , wherein each Ris —CF.11. The compound of claim 1 , wherein Ris selected from the group consisting of H and Calkyl.12. The compound of claim 1 , wherein Ris H.15. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of .16. A method of treating a disorder or condition through modulating a glucocorticoid receptor claim 1 , the method comprising administering to a subject in need of such treatment claim 1 , a therapeutically effective amount of a compound of claim 1 , thereby treating the disorder or condition.17. A method of treating a disorder or condition through antagonizing a glucocorticoid receptor claim 1 , the method comprising administering to a subject in need of such treatment claim 1 , an effective amount of the compound of .18. The method of claim 17 , wherein the disorder or condition is selected from the group consisting of obesity claim 17 , diabetes claim 17 , cardiovascular disease claim 17 , hypertension claim 17 , Syndrome X claim 17 , depression claim 17 , anxiety claim 17 , glaucoma claim 17 , human ...

Подробнее
21-03-2013 дата публикации

ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS

Номер: US20130072488A1

Aralkyl diamine derivative of the following formula, pharmaceutically acceptable salts or uses thereof as antidepressants. The derivatives have triplex inhibiting activities of the reuptake of 5-HT, dopamine and noradrenalin, which can be administered to the patients in need of such treatment in the form of compositions orally or injectedly et al. 2. The compound according to claim 1 , wherein the substituted amino group is an amino group substituted with C-Calkyl or C-Chaloalkyl.3. The compound according to claim 1 , wherein the substituted phenyl or the substituted benzyl has 1-4 substituents on the benzene ring claim 1 , with R claim 1 , Rand Rrepresenting the substituents.4. The compound according to claim 1 , wherein the salt is a pharmaceutically acceptable inorganic or organic salt.5. The compound according to claim 4 , wherein the hydrate contains 0.5-3 molecules of crystal water.6. The compound according to claim 1 , wherein the compound is selected from the group consisting of:VI-1 N,N-diethyl-3-(3,4-dichlorophenyl)-3-(pyrrolidin-1-yl)-propylamine,VI-2 N,N-dimethyl-3-(3,4-dichlorophenyl)-3-(pyrrolidin-1-yl)-propylamine,VI-3 N,N-dimethyl-3-(3,4-dichlorophenyl)-3-(piperazin-1-yl)-propylamine,VI-4 N,N-dimethyl-3-(3,4-dichlorophenyl)-3-morpholinyl-propylamine,VI-5 N-methyl-N-benzyl-3-(3,4-dichlorophenyl)-3-morpholinyl-propylamine,VI-6 4-(3-(3,4-dichlorophenyl)-3-(pyrrolidin-1-yl)propylmorpholine,VI-7 N,N-dimethyl-3-(3,4-dichlorophenyl)-3-piperidyl-propylamine,VI-8 N,N-dimethyl-3-(4-chlorophenyl)-3-morpholinyl-propylamine,VI-9 4-(3-(4-chlorophenyl)-3-(pyrrolidin-1-yl)propylmorpholine,VI-10 N,N-dimethyl-3-(4-methylphenyl)-3-morpholinyl-propylamine,VI-11 4-(3-(4-methylpiperazin-1-yl)-1-(4-methylphenyl)propylmorpholine,VI-12 4-(3-(4-methylphenyl)-3-(morpholinyl)propylpyrrole,VI-13 N,N-dimethyl-3-(benzothiophen-3-yl)-3-(pyrrolidin-1-yl)-propylamine,VI-14 N-methyl-N-benzyl-3-(benzothiophen-3-yl)-3-(pyrrolidin-1-yl)-propylamine,VI-15 N-methyl-3-(benzothiophen-3-yl)-3 ...

Подробнее
28-03-2013 дата публикации

USES OF SELECTIVE INHIBITORS OF HDAC8 FOR TREATMENT OF INFLAMMATORY CONDITIONS

Номер: US20130078215A1
Принадлежит: Pharmacyclics, Inc.

Described herein are methods for treating a subject suffering from an inflammatory, autoimmune, or heteroimmune condition by administering to the subject a pharmaceutical composition containing a therapeutically effective amount of a compound that is a selective inhibitor of histone deacetylase 8. Also described herein are methods for decreasing secretion of pro-inflammatory cytokines by administering an HDAC8-selective inhibitor compound. Further described herein are methods for predicting responsiveness to treatments for inflammatory conditions. Methods for predicting efficacy of treatments for inflammatory conditions are also described. 1. A method for treating an inflammatory condition in a subject in need thereof , comprising administering to the subject a composition containing a therapeutically effective amount of a selective inhibitor of histone deacetylase 8 activity.2. The method of claim 1 , wherein (a) the secretion of IL-1β in a sample taken from the subject is inhibited by at least 40% claim 1 , and/or (b) the swelling on the skin of the subject decreases by at least 30% after administering the therapeutically effective amount of the selective inhibitor of histone deacetylase 8 activity.3. The method of claim 1 , wherein the inflammatory condition is a skin inflammatory condition claim 1 , autoimmune condition claim 1 , or heteroimmune condition.4. The method of claim 1 , wherein the inflammatory condition is rheumatoid arthritis or psoriasis.5. The method of claim 1 , wherein the subject is refractory or intolerant to at least one other treatment for an inflammatory condition.6. The method of claim 1 , wherein the composition is administered in combination with an additional anti-inflammatory agent.7. The method of claim 6 , wherein the additional anti-inflammatory agent is an immunosuppressant claim 6 , glucocorticoid claim 6 , non-steroidal anti-inflammatory drug claim 6 , Cox-2 specific inhibitor claim 6 , leflunomide claim 6 , gold thioglucose ...

Подробнее
28-03-2013 дата публикации

Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands

Номер: US20130079320A1
Принадлежит: GRUENENTHAL GmbH

The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders. 2. The substituted compound according to claim 1 , wherein{'sup': 1', '2', '9', '10, 'sub': 2', '2, 'claim-text': [{'sup': '9', 'sub': 3', '2', '5, 'wherein Rrepresents H, CH, or CH, and'}, {'sup': '10', 'sub': 2', '3', '2', '5, 'wherein Rrepresents NH, CH, or CH,'}], 'one of residues Rand Rdenotes CH—N(R)—S(═O)—R,'}{'sup': 1', '2, 'sub': 3', '2', '2', '3', '3', '3, 'and the respective remaining residue of Rand Ris selected from the group consisting of H, F, Cl, Br, I, CH, CH—OH, CH—O—CH, CF, OH, and O—CH.'}3. The substituted compound according to claim 1 , wherein{'sup': 2', '9', '10, 'sub': 2', '2, 'claim-text': [{'sup': '9', 'sub': 3', '2', '5, 'wherein Rrepresents H, CH, or CH, and'}, {'sup': '10', 'sub': 2', '3', '2', '5, 'wherein Rrepresents NH, CH, or CH,'}], 'Rdenotes CH—N(R)—S(═O)—R,'}{'sup': '1', 'sub': 3', '2', '2', '3', '3', '3, 'and Ris selected from the group consisting of H, F, Cl, Br, I, CH, CH—OH, CH—O—CH, CF, OH, and O—CH.'}4. The substituted compound according to claim 1 , wherein{'sup': '3', 'sub': 3', '3', '3, 'Ris selected from the group consisting of H, F, Cl, CH, CF, OH and O—CH.'}5. The substituted compound according to claim 1 , whereinZ represents N and{'sup': '4a', 'Rrepresents H,'}or{'sup': '4b', 'claim-text': {'sup': '4b', 'sub': '3', 'wherein Rrepresents H or CH, and'}, 'Z represents C—R,'}{'sup': '4a', 'Rrepresents H.'}6. The substituted compound according to claim 1 , wherein{'sup': '5', 'Rrepresents H.'}7. The substituted compound according to claim 1 , whereinX represents N.8. The substituted compound according to claim 1 , wherein{'sup': '6', 'sub': '3', 'Rrepresents CF, tert.-Butyl or cyclopropyl.'}9. The substituted compound according to claim 1 , ...

Подробнее
28-03-2013 дата публикации

CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES

Номер: US20130079362A1
Принадлежит: DECIPHERA PHARMACEUTICALS, LLC

Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including, but not limited to, malignant melanomas, solid tumors, glioblastomas, ovarian cancer, pancreatic cancer, prostate cancer, lung cancers, breast cancers, kidney cancers, hepatic cancers, cervical carcinomas, metastasis of primary tumor sites, myeloproliferative diseases, chronic myelogenous leukemia, leukemias, papillary thyroid carcinoma, non-small cell lung cancer, mesothelioma, hypereosinophilia syndrome, gastrointestinal stromal tumors, colonic cancers, ocular diseases characterized by hyperproliferation leading to blindness including various retinopathies, diabetic retinopathy, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, mastocytosis, mast cell leukemia, and diseases caused by PDGFR-α kinase, PDGFR-β kinase, c-KIT kinase, cFMS kinase, c-MET kinase, and oncogenic forms, aberrant fusion proteins and polymorphs of any of the foregoing kinases. 12. A compound selected from the group consisting of N-(2 ,3-difluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1 ,1-dicarboxamide ,N-(3-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,N-benzyl-N′-(2,3-difluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)cyclopropane-1,1-dicarboxamide,N-benzyl-N′-(3-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)cyclopropane-1,1-dicarboxamide,N-(3-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-phenylcyclopropane-1,1-dicarboxamide,N-(3-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-(3-(trifluoromethyl)phenyl)cyclopropane-1,1-dicarboxamide,N-(2-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,N-(3-fluoro-4-(2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yloxy)phenyl)-N′-(4-methoxyphenyl)cyclopropane-1,1-dicarboxamide,N-(3-fluoro ...

Подробнее
28-03-2013 дата публикации

TRICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF

Номер: US20130079374A1
Принадлежит: Takeda Pharmaceutical Company Limited

The present invention provides a compound represented by the formula 123-. (canceled)26. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s).27. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).28. The compound of claim 24 , wherein Ris a hydrogen atom or Calkyl optionally having substituent(s).29. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s).30. The compound of claim 24 , wherein Ris a hydrogen atom claim 24 , Calkyl optionally having substituent(s) claim 24 , Calkenyl optionally having substituent(s) or amino optionally having substituent(s).31. The compound of claim 24 , wherein Rand Rare the same or different and each is a hydrogen atom claim 24 , a halogen atom claim 24 , hydroxy optionally having a substituent or Calkyl optionally having substituent(s).32. The compound of claim 24 , wherein Ris Calkyl optionally having substituent(s) claim 24 , Ccycloalkyl optionally having substituent(s) or Calkenyl optionally having substituent(s);{'sup': '2', 'Ris a hydrogen atom, a hydrocarbon group optionally having substituent(s) or a heterocyclic group optionally having substituent(s);'}{'sup': '3', 'sub': 1-6', '2-6, 'Ris a hydrogen atom, Calkyl optionally having substituent(s), Calkenyl optionally having substituent(s) or amino optionally having substituent(s);'}{'sup': 4a', '4b, 'sub': '1-6', 'Rand Rare the same or different and each is a hydrogen atom, a halogen atom, hydroxy optionally having a substituent or Calkyl optionally having substituent(s);'}{'sup': '5', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s); and'}{'sup': '6', 'sub': '1-6', 'Ris a hydrogen atom or Calkyl optionally having substituent(s).'}33. The compound of claim ...

Подробнее
11-04-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130089624A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 2. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.3. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.4. The method of claim 3 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.56-. (canceled)76. The method of claim claim 3 , wherein said DNA-damaging agent is selected from ionizing radiation claim 3 , a platinating agent claim 3 , a Topo I inhibitor claim 3 , a Topo II inhibitor claim 3 , an antimetabolite claim 3 , an alkylating agent claim 3 , or an alkyl sulphonates.816-. (canceled)176. The method of claim claim 3 , wherein the DNA-damaging agent is selected from one or more of the following: Cisplatin claim 3 , Carboplatin claim 3 , gemcitabine claim 3 , Etoposide claim 3 , Temozolomide claim 3 , or ionizing radiation.18. (canceled)19. The method of claim 3 , wherein said cancer is selected from a cancer of the ...

Подробнее
18-04-2013 дата публикации

USE OF ISOQUINOLONES FOR PREPARING DRUGS, NOVEL ISOQUINOLONES AND METHOD FOR SYNTHESISING SAME

Номер: US20130096083A1
Принадлежит:

The use of isoquinolones for preparing drugs, including novel isoquinolones as well as their synthesis method. In particular, isoquinolone derivatives used in the treatment of pathological angiogenesis, and more particularly of cancer. 136-. (canceled)38) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to .39) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to claim 37 , as a protein phosphatase 1 inhibitor claim 37 , vascular-disrupting agent and antiproliferative agent.40) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to claim 37 , as a tubulin polymerization inhibitor claim 37 , vascular-disrupting agent and antiproliferative agent.41) A method for the prevention and treatment of mammals claim 37 , in particular humans claim 37 , suffering from pathological angiogenesis claim 37 , in particular retinopathies claim 37 , or benign or malignant (cancerous) tumours claim 37 , comprising administering to a mammal in need thereof an effective amount of at least one compound of general formula (I) according to ...

Подробнее
18-04-2013 дата публикации

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

Номер: US20130096122A1
Принадлежит: Gilead Sciences, Inc.

The present invention relates to sodium channel inhibitors of Formula I: 2. The compound of claim 1 , wherein Xand Xare both —CH═.3. The compound of claim 2 , wherein Ris hydrogen or alkyl of 1-6 carbon atoms optionally substituted by hydroxy claim 2 , —C(O)R claim 2 , trifluoromethyl claim 2 , alkoxy of 1-6 carbon atoms claim 2 , or phenyl optionally substituted by —C(O)R.4. The compound of claim 3 , wherein R claim 3 , R claim 3 , and Rare hydrogen or lower alkyl of 1-6 carbon atoms.5. The compound of claim 4 , wherein Ris phenyl optionally substituted by 1 or 2 substituents independently selected from halo claim 4 , trifluoromethyl claim 4 , trifluoromethoxy claim 4 , cyano claim 4 , or —C(O)R claim 4 ,6. The compound of claim 5 , wherein Ris hydrogen claim 5 , R claim 5 , R claim 5 , R claim 5 , and Rare hydrogen claim 5 , Ris methoxy claim 5 , and Ris 6-(4-chlorophenyl) claim 5 , namely 6-(4-chlorophenyl)-7-methoxy-3 claim 5 ,4-dihydroquinolin-2(1H)-one.7. The compound of claim 5 , wherein Ris 2-methoxyethyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(4-trifluoromethylphenyl) claim 5 , namely 1-(2-methoxyethyl)-6-(4-(trifluoromethyl)phenyl)-3 claim 5 ,4-dihydroquinolin-2(1H)-one.8. The compound of claim 5 , wherein Ris carboxymethyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(4-trifluoromethoxyphenyl) claim 5 , namely 2-(2-oxo-6-(4-(trifluoromethoxy)phenyl)-3 claim 5 ,4-dihydroquinolin-1(2H)-yl)acetic acid.9. The compound of claim 5 , wherein Ris hydrogen claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(3-fluorophenyl) claim 5 , namely 6-(3-fluorophenyl)-3 claim 5 ,4-dihydroquinolin-2(1H)-one.10. The compound of claim 5 , wherein Ris benzyl claim 5 , R claim 5 , R claim 5 , R claim 5 , Rand Rare hydrogen claim 5 , and Ris 6-(2 claim 5 ,4-difluorophenyl) claim 5 , namely 1-benzyl-6-(2 claim 5 ,4-difluorophenyl)-3 claim 5 ,4-dihydroquinolin-2( ...

Подробнее
18-04-2013 дата публикации

5-ARYL ISOXAZOLINES FOR CONTROLLING PESTS

Номер: US20130096124A1
Принадлежит:

The present invention relates to new isoxazoline compounds of formula 2. A compound of formula (I) according to claim 1 , wherein Q is C-C-alkoxy; C-C-haloalkoxy; C-C-alkylthio; C-C-haloalkylthio; NRR; COR; COR; C-C-alkyl which is unsubstituted or substituted by C-C-cycloalkyl claim 1 , halogen claim 1 , cyano claim 1 , nitro claim 1 , hydroxy claim 1 , C-C-alkoxy claim 1 , C-C-haloalkoxy claim 1 , C-C-alkylthio claim 1 , C-C-haloalkylthio claim 1 , C-C-alkylsulfinyl claim 1 , C-C-haloalkylsulfinyl claim 1 , C-C-alkylsulfonyl claim 1 , C-C-haloalkylsulfonyl claim 1 , C-C-alkylcarbonylamino claim 1 , C-C-haloalkylcarbonylamino claim 1 , C-C-alkoxycarbonyl claim 1 , sulfonamido claim 1 , N-mono- or N claim 1 ,N claim 1 , di-C-C-alkylsulfonamido claim 1 , N-mono- or N claim 1 ,N-di-C-C-alkylaminocarbonyl claim 1 , N-mono- or N claim 1 ,N-di-C-C-haloalkylaminocarbonyl claim 1 , C-C-alkanoyl claim 1 , unsubstituted or C-C-alkyl- claim 1 , C-C-haloalkyl- claim 1 , C-C-alkoxy- claim 1 , C-C-haloalkoxy- claim 1 , halogen- claim 1 , cyano- or C-C-alkoxycarbonyl-substituted C-C-aryl claim 1 , or unsubstituted or C-C-alkyl- claim 1 , C-C-haloalkyl- claim 1 , C-C-alkoxy- claim 1 , C-C-haloalkoxy- claim 1 , halogen- claim 1 , cyano- or C-C-alkoxycarbonyl-substituted 4- to 6-membered heterocyclyl; C-C-alkenyl; C-C-alkynyl; C-C-cycloalkyl which is unsubstituted or substituted by halogen claim 1 , C-C-alkyl or C-C-haloalkyl; C-C-aryl unsubstituted or substituted by C-C-alkyl claim 1 , C-C-haloalkyl claim 1 , C-C-alkoxy claim 1 , C-C-haloalkoxy claim 1 , halogen claim 1 , cyano or C-C-alkoxycarbonyl; or 4- to 6-membered heterocyclyl unsubstituted or substituted by C-C-alkyl claim 1 , C-C-haloalkyl claim 1 , C-C-alkoxy claim 1 , C-C-haloalkoxy claim 1 , halogen claim 1 , cyano or C-C-alkoxycarbonyl;{'sub': 7', '8', '1', '6', '1', '6', '3', '6, 'Rand Rare each independently of the other H, C-C-alkyl, C-C-haloalkyl or C-C-cycloalkyl;'}{'sub': 1', '2', '3', '1', '2', '2', '3', '3', '4', ...

Подробнее
18-04-2013 дата публикации

HETEROARYL COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

Номер: US20130096149A1
Принадлежит: NOVARTIS AG

The present invention provides compounds of Formula I: 4. (canceled)5. A compound of claim 3 , wherein:X represents O or S;{'sup': '1', 'Ris selected from t-butyl, cyclo-propyl, and substituted phenyl;'}{'sup': 2', '11, 'Ris pyrimidinyl substituted with R;'}{'sup': 3', '12', '13', '15, 'Ris phenyl substituted with R, R, and R;'}{'sup': '11', 'sub': '2', 'Ris NH;'}{'sup': '12', 'Ris Cl or F;'}{'sup': '13', 'sub': 2', '1-3, 'Ris NHSO—Calkyl; and'}{'sup': '15', 'sub': '3', 'Ris selected from F, Br, CH, H, and Cl.'}6. A compound of wherein X represents O.7. A compound of wherein X represents S.8. A compound of wherein:{'sup': '1', 'Rrepresents cyclopropyl; and'}{'sup': '15', 'Rrepresents Cl or F.'}9. (canceled)10. The compound of selected from the group consisting of:N-(3-(5-(2-aminopyrimidin-4-yl)-2-cyclopropylthiazol-4-yl)-5-chloro-2-fluorophenyl)propane-1-sulfonamide; (S)-methyl 1-(4-(4-(5-chloro-2-fluoro-3-(propylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate; N-(2,5-dichloro-3-(2-cyclopropyl-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)phenyl)propane-1-sulfonamide;N-(3-(5-(2-aminopyrimidin-4-yl)-2-cyclopropylthiazol-4-yl)-2,5-dichlorophenyl)propane-1-sulfonamide;(S)-methyl 1-(4-(4-(2-chloro-5-fluoro-3-(propylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate; andN-(2-chloro-3-(2-cyclopropyl-5-(2-(methylamino)pyrimidin-4-yl)thiazol-4-yl)-5-fluorophenyl)propane-1-sulfonamide; N-(3-(5-(2-aminopyrimidin-4-yl)-2-cyclopropyloxazol-4-yl)-5-chloro-2-fluorophenyl)propane-1-sulfonamide; andN-(3-(5-(2-aminopyrimidin-4-yl)-2-cyclopropyloxazol-4-yl)-2,5-dichlorophenyl)propane-1-sulfonamide.or a pharmaceutically acceptable salt thereof.11. A pharmaceutical composition comprising a compound of claim 1 , and a diluent claim 1 , carrier or excipient.12. The pharmaceutical composition of further comprising an additional therapeutic agent claim 11 , wherein said additional therapeutic agent is selected from ...

Подробнее
25-04-2013 дата публикации

COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS

Номер: US20130102597A1
Принадлежит: INTERMUNE, INC.

Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of the p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the p38 MAPK by the compound. Also disclosed are derivatives and analogs of pirfenidone, useful for modulating a stress activated protein kinase (SAPK) system. 3. The method of claim 2 , wherein{'sup': '1', 'Ris selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cyano, sulfonamido, halo, alkenylenearyl, and heteroaryl;'}{'sup': 2', '2', '1, 'sub': 3', '2', '2', '2', '2', '2, 'Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo, unsubstituted alkyl, alkenyl, OCF, NO, CN, NC, OH, alkoxy, haloalkoxy, amino, COH, and COalkyl; haloalkylcarbonyl; cycloalkyl; hydroxylalkyl; sulfonamide; unsubstituted cycloheteroalkyl and cycloheteroalkyl substituted with one to three substituents independently selected from alkyleneOH, C(O)NH, NH, aryl, haloalkyl, halo, and OH; or Rand Rtogether form an optionally substituted 5-membered nitrogen-containing heterocyclic ring;'}{'sup': '4', 'Ris selected from the group consisting of hydrogen, haloalkyl, alkoxy, alkenyl, and alkenylenearyl; and'}{'sup': '5', 'Xis hydrogen.'}4. The method of claim 1 , wherein one of X claim 1 , X claim 1 , and Xis not hydrogen.5. The method of claim 4 , wherein Ris selected from the group consisting of aryl; unsubstituted heteroaryl; heteroaryl substituted with one or more substituents selected from halo claim 4 , unsubstituted alkyl claim 4 , alkenyl claim 4 , OCF claim 4 , NO claim 4 , CN claim 4 , NC claim 4 , OH claim 4 , alkoxy claim 4 , haloalkoxy claim 4 , amino claim 4 , COH ...

Подробнее
25-04-2013 дата публикации

NOVEL CYCLOPROPANE INDOLINONE DERIVATIVES

Номер: US20130102604A1
Принадлежит: Hoffmann-La Roche Inc.

The present invention relates to a compound of formula (I) 2. A compound according to claim 1 , wherein one of Rand Ris selected from hydrogen and alkyl and the other is selected from the group consisting of: pyridinyl claim 1 , halophenyl claim 1 , alkylsulfonylphenyl claim 1 , cyanophenyl and trifluoromethylphenyl.3. A compound according to claim 1 , wherein one of Rand Ris selected from hydrogen and isopropyl and the other is selected from the group consisting of: pyridinyl claim 1 , fluorophenyl claim 1 , chlorophenyl claim 1 , cyanophenyl claim 1 , methylsulfonylphenyl and trifluoromethylphenyl.4. A compound according to wherein Ris selected from the group consisting of: pyridinyl claim 1 , carboxypyridinyl claim 1 , tetrahydropyranyl claim 1 , dialkylamino claim 1 , morpholinyl claim 1 , alkylsulfonylpiperidinyl claim 1 , alkylpiperazinyl claim 1 , dialkylaminoalkylpiperazinyl claim 1 , dialkylaminopyrrolidinyl claim 1 , carboxyalkyl-1H-imidazolyl claim 1 , carboxy-1H-imidazolyl or substituted phenyl claim 1 , wherein substituted phenyl is phenyl substituted with one or two substituents independently selected from alkyl claim 1 , halogen claim 1 , carboxy claim 1 , alkylsulfonyl claim 1 , alkylaminocarbonyl claim 1 , alkylsulfonylaminocarbonyl claim 1 , piperidinylcarbonyl claim 1 , piperazinylcarbonyl claim 1 , morpholinylcarbonyl claim 1 , pyridinylpiperazinylcarbonyl claim 1 , alkylpiperazinylcarbonyl claim 1 , alkylsulfonylpiperazinylcarbonyl claim 1 , alkylpyrrolidinylalkylaminocarbonyl claim 1 , alkyl-1H-pyrazolylaminocarbonyl claim 1 , oxo-oxazolidinyl claim 1 , oxo-pyrrolidinyl and oxo-imidazolidinyl.5. A compound according to claim 1 , wherein Ris selected from the group consisting of: carboxypyridinyl claim 1 , carboxyalkyl-1H-imidazolyl claim 1 , carboxyphenyl and phenyl substituted with carboxy and oxo-oxazolidinyl.6. A compound according to claim 1 , wherein Ris selected from the group consisting of: hydrogen claim 1 , halogen and carboxy.7. A ...

Подробнее
25-04-2013 дата публикации

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

Номер: US20130102632A1
Принадлежит: Gilead Sciences, Inc.

The present invention relates to sodium channel inhibitors of Formula (I): 2. The compound of claim 1 , wherein Ris alkyl of 1-3 carbon atoms or phenyl optionally substituted by halo.3. The compound of claim 2 , wherein R claim 2 , Rand Rare independently chosen from hydrogen and halo.4. The compound of claim 3 , wherein Ris alkyl of 1-6 carbon atoms.5. The compound of claim 4 , wherein X is a covalent bond claim 4 , —C(O)O— claim 4 , or heteroaryl claim 4 , Y is methylene claim 4 , and Z is cycloalkyl or phenyl claim 4 , both of which are optionally substituted by halo or heteroaryl.6. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is 2-bromophenyl claim 5 , namely 2-bromobenzyl 2 claim 5 ,4-dimethylquinoline-3-carboxylate.7. The compound of claim 5 , wherein Ris methyl claim 5 , Ris phenyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is phenyl claim 5 , namely benzyl 2-methyl-4-phenylquinoline-3-carboxylate.8. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is 4-chlorophenyl claim 5 , namely 4-chlorobenzyl 2 claim 5 ,4-dimethylquinoline-3-carboxylate.9. The compound of claim 5 , wherein Rand Rare both methyl claim 5 , R claim 5 , R claim 5 , and Rare all hydrogen claim 5 , X is a covalent bond claim 5 , Y is 1 claim 5 ,3 claim 5 ,4-oxadiazole claim 5 , and Z is (4-chlorophenyl)propan-2-yl) claim 5 , namely 2-(2-(4-chlorophenyl)propan-2-yl)-5-(2 claim 5 ,4-dimethylquinolin-3-yl)-1 claim 5 ,3 claim 5 ,4-oxadiazole.10. The compound of claim 5 , wherein Ris methyl claim 5 , Ris phenyl claim 5 , Rand Rare hydrogen claim 5 , Ris 6-chloro claim 5 , X is —C(O)O— claim 5 , Y is methylene claim 5 , and Z is cyclopropyl claim 5 , namely ...

Подробнее
25-04-2013 дата публикации

SUBSTITUTED DIKETOPIPERAZINES AND THEIR USE AS OXYTOCIN ANTAGONISTS

Номер: US20130102783A1
Автор: Liddle John
Принадлежит: Glaxo Group Limited

Compounds of formula (1) 1. A compound which is {(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1R)-1-methylpropyl]-2,5-dioxo-1-piperazinyl}(2-methyl-1,3-oxazol-4-yl)acetic acid. This application is a Continuation of U.S. patent application Ser. No. 13/231,211 filed Sep. 13, 2011, now allowed; which is a Continuation of U.S. patent application Ser. No. 10/561,498 filed Dec. 19, 2005, issued as U.S. Pat. No. 8,071,594; which was filed pursuant to 35 U.S.C. §371 as a U.S. National Phase Application of International Patent Application No. PCT/EP2004/006814 filed Jun. 22, 2004, which claims priority from Great Britain Application No. 0314738.6 filed Jun. 24, 2003.This invention relates to novel diketopiperazine derivatives having a potent and selective antagonist action at the oxytocin receptor, to processes for their preparation, pharmaceutical compositions containing them and to their use in medicine.The hormone oxytocin is potent contractor of the uterus and is used for the induction or augmentation of labour. Also the density of uterine oxytocin receptors increases significantly by >100 fold during pregnancy and peaks in labour (pre-term and term).Pre-term births/labour (between 24 and 37 weeks) causes about 60% of infant mortality/morbidity and thus a compound which inhibits the uterine actions of oxytocin e.g. oxytocin antagonists, should be useful for the prevention or control of pre-term labour.International patent application PCT/EP02/14823 describes a class of diketopiperazine derivatives which exhibit a particularly useful level of activity as selective antagonists at the oxytocin receptor. A preferred class of compounds described therein is represented by the formula ASuch compounds include those wherein inter alia Ris 2-indanyl, Ris Calkyl, Ris a 5 or 6 membered heteroaryl group linked to the rest of the molecule via a carbon atom in the ring, Rrepresents the group NRRwherein Rand Reach represent alkyl e.g. methyl or Rand Rtogether with the nitrogen atom to ...

Подробнее
02-05-2013 дата публикации

PREPARATION METHOD OF 5-[[2(R)-[1(R)-[3,5-BIS(TRIFLUOROMETHYL) PHENYL]ETHOXY]-3(S)-4-FLUOROPHENYL-4-MORPHOLINYL]METHYL]-1,2-DIHYDRO-3H-1,2,4-TRIAZOLE-3-ONE

Номер: US20130109853A1
Принадлежит:

Disclosed is a synthesis method of a compound of formula 1,5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl)phenyl]ethoxyl]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one (i.e. aprepitant), which comprises cyclizing a compound of formula 4 in a solvent, wherein R is C-Calkyl. The intermediate for preparing aprepitant is also disclosed. The present method is especially suitable for industrial production of aprepitant. 2. The method according to claim 1 , wherein R is selected from methyl claim 1 , ethyl and t-butyl.3. The method according to claim 1 , wherein the alcohol is C-Cfatty alcohol claim 1 , preferably selected from methanol claim 1 , ethanol claim 1 , propanol claim 1 , n-butanol claim 1 , t-butanol and propanediol; the ester is an organic acid ester claim 1 , preferably selected from ethyl acetate claim 1 , methyl acetate claim 1 , ethyl formate and t-butyl acetate; and the ether is selected from tetrahydrofuran claim 1 , dioxane and 3-methyl tetrahydrofuran.4. The method according to claim 1 , wherein the solvent is alcohol claim 1 , water or alcohol-water mixed solvent.5. The method according to claim 1 , wherein the solvent is ethanol-water mixed solvent.6. The method according to claim 5 , wherein the volume ratio of the ethanol-water mixed solvent is 1:0.1 to 1:100.7. The method according to claim 1 , wherein the solvent is the ether-water mixed solvent claim 1 , preferably a tetrahydrofuran-water mixed solvent with a volume ratio of 1:0.1 to 1:100.8. The method according to claim 1 , wherein the cyclization reaction is performed under the action of an inorganic base.9. The method according to claim 1 , wherein the temperature of the cyclization reaction is 60 to 100° C.11. The method according to claim 8 , wherein the inorganic base is selected from KHCO claim 8 , KCO claim 8 , NaCO claim 8 , NaHCO claim 8 , KOH claim 8 , NaOH and CsCO.12. The method according to claim 8 , wherein the inorganic base is KOH or NaOH.13. The method ...

Подробнее
09-05-2013 дата публикации

Compounds Useful as Inhibitors of ATR Kinase

Номер: US20130115312A1
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. 43. The compound of any one of - claims 1 , wherein Q is phenyl.5. The compound of claim 4 , wherein p is 0; q is 1; and Jis a Caliphatic group wherein one methylene unit is replaced with S(O).6. The compound of claim 5 , wherein Jis SOCH(CH).7. The compound of wherein Ring B is phenyl.8. The compound of claim 1 , wherein n and m are both 0.10. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable carrier.11. A method for treating cancer in a patient comprising administering a compound of or a pharmaceutically acceptable derivative thereof.12. The method of claim 11 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent; wherein said additional therapeutic agent is appropriate for the disease being treated; and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.1328-. (canceled)29. The method of claim 11 , wherein said cancer is selected from non-small cell lung cancer claim 11 , small cell lung cancer claim 11 , pancreatic cancer claim 11 , biliary tract cancer claim 11 , head and neck cancer claim 11 , bladder cancer claim 11 , colorectal cancer claim 11 , ...

Подробнее
09-05-2013 дата публикации

NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A

Номер: US20130116229A1
Принадлежит:

The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders. 2. The compound of claim 1 , where Ris selected from the group consisting of halogen claim 1 , CN claim 1 , OH claim 1 , C-C-alkyl claim 1 , fluorinated C-C-alkyl claim 1 , C-C-alkoxy claim 1 , fluorinated C-C-alkoxy claim 1 , C-C-cycloalkyl claim 1 , fluorinated C-C-cycloalkyl claim 1 , N(R)(R) claim 1 , C-C-alkyl-N(R)(R) claim 1 , C(O)O—R claim 1 , C(O)N(R)(R) claim 1 , N(R)S(O)(R) and S(O)N(R)(R).3. The compound of claim 1 , where Xis C—H.4. The compound of claim 1 , where Xis N.5. The compound of claim 1 , where Xis C—R.6. The compound of claim 1 , where Xis N.7. The compound of claim 1 , where Y is O.8. The compound of claim 1 , where Ris C-C-alkyl claim 1 , C-C-cycloalkyl or C-C-cycloalkylmethyl.9. The compound of claim 8 , where Ris a radical of the formula CHRR claim 8 , where Ris selected from the group consisting of hydrogen and C-C-alkyl and where Ris selected from the group consisting of C-C-alkyl.10. The compound of claim 1 , where Ris a moiety Z—Ar.11. The compound of claim 1 , where Ris a radical of the formula CRRR.12. The compound of claim 11 , where{'sup': 21', '22', 'g', 'h', 'h', 'g, 'sub': '2', 'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'Rand Rtogether with the carbon atom, to which they are bound form a saturated 5- to 7-membered carbocyclic ring or a saturated 5- to 7-membered heterocyclic ring which has 1, 2 or 3 heteroatoms or heteroatom containing groups selected from the group of O, N, S, SO and SOas ring members, where the carbocyclic ring and the heterocyclic ring may be unsubstituted or may be substituted by 1, 2 or 3 identical or different ...

Подробнее
16-05-2013 дата публикации

MODULATORS OF CENTRAL NERVOUS SYSTEM NEUROTRANSMITTERS

Номер: US20130123253A1
Автор: CASHMAN John
Принадлежит: HUMAN BIOMOLECULAR RESEARCH INSTITUTE

Disclosed are agents having pharmacological activity against cellular receptors and intracellular signaling, particularly receptors and signaling pathways of central nervous system (CNS) neurotransmitters. Also disclosed are related methods and compositions for the treatment or prevention of diseases or disorders using the agents. 3. A compound of claim 2 , wherein G is hydrogen or combined with Rto form a 5-6 membered heterocylcoalkyl containing 1-2 heteroatoms each independently selected from the group consisting of N and 0; and subscript b is 1-3.4. A compound of claim 3 , wherein D is a member selected from the group consisting of optionally substituted phenyl claim 3 , optionally substituted naphthyl and optionally substituted bi-phenyl; and subscript a is 0-3.5. A compound of claim 3 , selected from the group consisting of:2-(aminomethyl)-5-phenyltetrahydrofuran,2-(aminomethyl)-5-(4′-chlorophenyl)tetrahydrofuran,2-(aminomethyl)-5-(4-bromophenyl)tetrahydrofuran,2-(aminomethyl)-5-(4-methoxyphenyl)tetrahydrofuran,2-(aminomethyl)-5-(4′-t-butylphenyl)tetrahydrofuran,trans-2-(aminomethyl)-5-(2′-methoxy-5′-fluorophenyl)tetrahydrofuran,cis-2-(aminomethyl)-5-(2′-methoxy-5-fluorophenyl)tetrahydrofuran,2-(aminomethyl)-5-(3′-fluoro-4′-methylphenyl)tetrahydrofuran,2-(aminomethyl)-5-cyclohexyltetrahydrofuran,2-(aminomethyl)-5-(1′-naphthyl)tetrahydrofuran,2-(aminomethyl)-5-(2′-naphthyl)tetrahydrofuran,2-(aminomethyl)-5-(2′-naphthyl)tetrahydrofuran,2-(aminoethyl)-5-phenyltetrahydrofuran,2-(aminoethyl)-5-(4′-fluorophenyl)tetrahydrofuran,2-(aminoethyl)-5-(4′-bromophenyl)tetrahydrofuran,2-(aminoethyl)-5-(4′-t-butylphenyl)tetrahydrofuran,trans-7 aminoethyl)-5-(2′-methoxy-5′-fluorophenyl)tetrahydrofuran,cis-2-(aminoethyl)-5-(2′-methoxy-5′-fluorophenyl)tetrahydrofuran,2-(aminoethyl)-5-cyclohexyltetrahydrofuran,2-(aminoethyl)-5-(2′-furyl)tetrahydrofuran,2-(aminomethyl)-5-benzyltetrahydrofuran,2-(aminoethyl)-5-benzyltetrahydrofuran,trans-2-(aminomethyl)-5-(2′-methoxy-5′-fluorobenzyl) ...

Подробнее
16-05-2013 дата публикации

4(1H)-Quinolones Having Antimalarial Activity With Reduced Chemical Resistance

Номер: US20130123258A1
Принадлежит:

Provided are 4(1H)-quinolone derivatives effective in inhibiting or eliminating the viability of at least one of the stages in the life-cycle of the malarial parasite, and to show a reduced propensity to induce resistance to the compound by the target parasite. In particular, the compounds can be derivatives of phenoxyethoxy-quinolones, and including, but not only, 7-(2-phenoxyethoxy)quinolin derivatives. These compounds may be administered by themselves, with at least one other derivative compound, or with other antimalarial compounds, to an animal or human subject. The therapeutic compositions can be and formulated to reduce the extent of a infection in the recipient subject, or to reduce the likelihood of the onset or establishment of a infection if administered prior to the parasite contacting the subject. The therapeutic compositions can be formulated to provide an effective single dose amount of an antimalarial compound or multiple doses for administering over a period of time. 2. The compound of having the Formula I.3. The compound of claim 2 , wherein the compound is selected from the group consisting of: 6-butyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (15) claim 2 , 6-butyl-3-ethyl-2-methyl-7-(2-phenoxyethoxy)quinolin-4(1H)-one (16) claim 2 , 6-chloro-3-ethyl-2-methyl-7-(2-phenoxy-ethoxy)-1H-quinolin-4-one (17) claim 2 , 3-ethyl-2 claim 2 ,6-dimethyl-7-(2-phenoxy-ethoxy)-1H-quiolin-4-one (18) claim 2 , 3-ethyl-6-methoxy-2-methyl-7-(2-phenoxy-methoxy)-1H-quinolin-4-one (19) claim 2 , 6-chloro-3-ethyl-7-methoxymethoxy-2-methyl-1H-quinoline-4-one (20) claim 2 , 6-chloro-3-ethyl-7-(3-hydroxy-propoxy)-2-methyl-1H-quinolin-4-one (21) claim 2 , 2-ethyl-3-oxo-butyricacid-3-(6-chloro-3-ethyl-2-methyl-4-oxo-1 claim 2 ,4-dihydro-quinolin-7-yloxy)-propyl ester (22) claim 2 , 6-chloro-3-ethyl-2-methyl-7-(2-morpholin-4-yl-ethoxy)-1H-quinolin-4-one (23) claim 2 , 6-chloro-7-(2-dimethylamino-ethoxy)-3-ethyl-2-methyl-1H-quinolin-4-one (24) claim 2 , 6-bromo-3-ethyl-2 ...

Подробнее
23-05-2013 дата публикации

SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF

Номер: US20130131044A1
Принадлежит:

The invention provides compounds of Formula (I) for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. 2. The compound of wherein said non-interfering substituent is selected from one or more of the group consisting of alkyl claim 1 , cycloalkyl claim 1 , alkenyl claim 1 , cycloalkenyl claim 1 , alkynyl claim 1 , aryl claim 1 , heteroaryl claim 1 , arylalkyl claim 1 , heteroarylalkyl claim 1 , arylalkenyl claim 1 , heteroarylalkenyl claim 1 , arylalkynyl claim 1 , and heteroarylalkynyl claim 1 , each of which may be optionally substituted with one or more heteroatoms or additional non-interfering substituents.36-. (canceled)89-. (canceled)10. The compound of wherein the compound is selected from the following group:rac-(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(methylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-(propylamino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(butylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(allylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-6-(hydroxymethyl)-2-((4-methoxybenzyl)amino)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(dimethylamino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;rac-(3aR,4R,5R,6R,7aS)-2-(ethyl(methyl)amino)-6-(hydroxymethyl)-3a,4,5,6,7,7a-hexahydrobenzo[d]oxazole-4,5-diol;(3aR,4R,5R,6R,7aS)-2-amino-6-(hydroxymethyl)-3a,4,5,6,7 ...

Подробнее
23-05-2013 дата публикации

Novel Estrogen Receptor Ligands

Номер: US20130131061A1
Принадлежит: KARO BIO AB

The invention provides a compound of formula (I) or a pharmaceutically acceptable ester, amide, carbamate, solvate or salt thereof, including a salt of such an ester, amide or carbamate, and a solvate of such an ester, amide, carbamate or salt. The invention also provides also provides the use of such compounds in the treatment or prophylaxis of a condition associated with a disease or disorder associated with estrogen receptor activity, wherein R, R, R, Rand Rare as defined in the specification. 125.-. (canceled)27. A method as claimed in claim 26 , in which each Ris independently selected from the group consisting of hydrogen claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , Ccycloalkyl claim 26 , phenyl and benzyl.28. A method as claimed in claim 27 , in which each Rindependently represents hydrogen or Calkyl.29. A method as claimed in claim 26 , in which each Ris independently selected from the group consisting of hydrogen and Calkyl.30. A method as claimed in claim 26 , in which is selected from the group consisting of OR claim 26 , N(R) claim 26 , —C(O)Calkyl claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , haloCalkyl claim 26 , dihaloCalkyl claim 26 , trihaloCalkyl claim 26 , haloCalkenyl claim 26 , dihaloCalkenyl claim 26 , trihaloCalkenyl claim 26 , phenyl claim 26 , and 5-6 membered heterocyclyl claim 26 , wherein said phenyl or heterocyclyl group can either be unsubstituted or substituted by 1 to 3 substituents selected from the group consisting of OR claim 26 , halogen claim 26 , cyano claim 26 , —C(O)Calkyl claim 26 , Calkyl claim 26 , Calkenyl claim 26 , Calkynyl claim 26 , haloCalkyl claim 26 , dihaloCalkyl and trihaloCalkyl.31. A method as claimed in claim 30 , in which Ris selected from the group consisting of OR claim 30 , N(R) claim 30 , —C(O)Calkyl claim 30 , Calkyl claim 30 , Calkenyl claim 30 , Calkynyl claim 30 , phenyl claim 30 , and 5-6 membered heterocyclyl claim 30 , wherein said phenyl or ...

Подробнее
30-05-2013 дата публикации

HETEROARYL-PYRAZOLE DERIVATIVE

Номер: US20130137865A1
Принадлежит: TAISHO PHARMACEUTICAL CO., LTD.

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like. 3. The compound or a pharmaceutically acceptable salt thereof according to , wherein in the formula [I] , ring A represents a phenyl group or a 6-membered heteroaryl group (wherein the phenyl group or 6-membered heteroaryl group is substituted with 1 to 3 substituents selected from the group consisting of —SONRR , —SOR , —NRSOR , a Calkyl group , an amino group , and a halogen atom , and R , R , R , Rand Rare as defined in ).4. The compound or a pharmaceutically acceptable salt thereof according to claim 1 , wherein{'sup': 1', 'f', 'f, 'sub': 2', 'n1', '2', 'n2', '2', 'n3', '2', 'n4', '2', 'n5', '2', 'n6', '2', 'n7', '2', 'n8', '2', 'n9, 'claim-ref': [{'@idref': 'CLM-00001', 'claim 1'}, {'@idref': 'CLM-00002', '2'}], 'Yrepresents —(CH)—, —(CH)—NR—(CH)—, —(CH)—O—(CH)—, —(CH)—NHC(═O)—(CH)—, —(CH)—C(═O)NH—(CH)—, ethynylene, piperazin-1,4-yl, phenylene, pyridylene, or 5-membered heteroarylene (wherein Rand n1 to n9 are as defined in or ), and'}{'sup': '2', 'sub': 1-6', '3-6', '1-6', '1-6', '3-6', '1-6, 'Yrepresents a phenyl group, a naphthyl group, a pyridyl group, a quinolyl group, or a partially saturated condensed polycyclic heteroaryl group {wherein the phenyl group, naphthyl group, pyridyl group, quinolyl group, or partially ...

Подробнее
30-05-2013 дата публикации

NUCLEIC ACID DETECTIONS AND METHODS OF THEIR USE

Номер: US20130137875A1
Автор: Ying Laiqiang
Принадлежит:

The invention describes the preparation and use of fluorescent stains for nucleic acids derived from unsymmetrical cyanine dyes, dimmers, trimers, or tetramers. In particular, the invention describes unsymmetric cyanine dyes, dimmers, trimer and tetramers having a water soluble substituent. The dyes of the invention possess superior fluorescent properties when complexed with nucleic acids, and have utility in any application which requires detection of nucleic acids, such as detection of nucleic acids in solution, in gels, in blots, in microarrays, and in bacteria and cells, and for use in analysis of cell structure, membrane integrity, and function. The presence of the water soluble substituent results in improved water soluability and stability, resulting in improved detection of nucleic acids. 2. The compound according to claim 1 , wherein X is O claim 1 , S.3. The compound according to claim 1 , wherein each of Ror Ris independently hydrogen claim 1 , carboxy claim 1 , sulfo claim 1 , halogen claim 1 , alkoxy claim 1 , alkylaminocarbonyl claim 1 , alkylaminosulfonamide.4. The compound according to claim 1 , wherein Ris alkyl claim 1 , arylalkyl claim 1 , alkyl group substituted by a carboxy claim 1 , a sulfo claim 1 , a phosphate.5. The compound according to claim 1 , wherein Ris H claim 1 , substituted phenyl.6. The compound according to claim 1 , wherein Ris H claim 1 , alkyl claim 1 , aryl claim 1 , halogen claim 1 , alkoxy claim 1 , alkylamino claim 1 , alkylthio.7. The compound according to claim 1 , wherein n is 0 or 1.8. The compound according to claim 1 , wherein Ris —(CH)[O—(CH)]—O—Z claim 1 , where Z is H claim 1 , alkyl; each of a and b is an integer from 1 to 3; m is an integer selected from 1 to 6.9. The compound according to claim 1 , wherein Ris H or sulfo claim 1 , Ris methyl or ethyl claim 1 , Ris H or methoxyl claim 1 , and Ris —(CH)[O—(CH)]—O—Z claim 1 , where Z is H claim 1 , methyl; each of a and b is an integer from 2 to 3; m is an integer ...

Подробнее
30-05-2013 дата публикации

Nitrogen-containing heterocyclic compound and pest control agent

Номер: US20130137876A1
Принадлежит: Nippon Soda Co Ltd

The present invention offers compounds or their salts expressed by formula (I) (in the formula, X indicates an alkyl group, or the like; Y indicates an alkyl group; Z indicates a respectively independent nitro group, or the like; n indicates any integer from 0 to 3; A indicates carbon atom, or the like, and hydrogen atom is bonded thereto in the case where the carbon atom is not substituted with Z; D indicates oxygen atom, or the like; W indicates hydrogen atom, or the like; R 1 and R 2 indicate respectively independent hydrogen atoms, or the like; R 1 and R 2 may be bonded, and may form a heterocycle together with the nitrogen atom between R 1 and R 2 ).

Подробнее
06-06-2013 дата публикации

CHEMICAL INDUCERS OF NEUROGENESIS

Номер: US20130143885A1

The present invention relates to compounds and methods for inducing neuronal differentiation in normal neural stem cells and brain cancer stem cells. The methods may take place in vitro, such as in isolates from the adult mammalian brain, or in vivo. Compounds and methods described herein may find use in the treatment of neurodegenerative and psychiatric diseases, the repair and regeneration of the nervous system, and in treatment of neurologic malignancy. 113-. (canceled)15. The method of claim 14 , wherein any alkyl group comprised in any of R claim 14 , R claim 14 , R claim 14 , R claim 14 , R claim 14 , or Ris lower alkyl.16. The method of claim 15 , wherein the cyclic group formed by Rand Ris cyclopropyl claim 15 , cyclobutyl claim 15 , or cyclopentyl.18. The method of claim 17 , wherein Y is S and Ris a substituted or unsubstituted C-Calkyl.19. The method of claim 17 , wherein Y is S and Ris a substituted or unsubstituted C-Ccycloalkyl.20. The method of claim 17 , wherein Y is O and Ris a substituted or unsubstituted C-Ccycloalkyl.21. The method of claim 17 , wherein Y is O and Ris a substituted or unsubstituted C-Calkyl.22. The method of claim 17 , wherein Y is S and Ris a substituted or unsubstituted C-Calkenyl claim 17 , C-Calkynyl or benzyl.23. The method of claim 17 , wherein Y is O and Ris a substituted or unsubstituted C-Calkenyl claim 17 , C-Calkynyl or benzyl.24. The method of claim 17 , wherein Ris H.25. The method of claim 17 , wherein said stem cell is located in an animal subject.26. The method of claim 17 , wherein said stem cell is contacted ex vivo.2844-. (canceled) This application claims the benefit of the filing dates of U.S. Provisional Application 60/829,338, filed Oct. 13, 2006 and U.S. Provisional Application 60/953,182, filed Jul. 31, 2007, the entire contents of each of which are hereby incorporated by reference.1. Field of the InventionThe present invention relates generally to the fields of cell biology, developmental biology and ...

Подробнее
06-06-2013 дата публикации

Human Adam-10 Inhibitors

Номер: US20130144056A1
Принадлежит: SYMPHONY EVOLUTION, INC.

The present invention provides compounds useful for inhibiting the ADAM-10 protein, with selectivity versus MMP-1. Such compounds are useful in the in vitro study of the role of ADAM-10 (and its inhibition) in biological processes. The present invention also comprises pharmaceutical compositions comprising one or more ADAM-10 inhibitors according to the invention in combination with a pharmaceutically acceptable carrier. Such compositions are useful for the treatment of cancer, arthritis, and diseases related to angiogenesis. Correspondingly, the invention also comprises methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role. 2. The compound according to claim 1 , wherein Lis —C(O)— or —S(O)—.3. The compound according to claim 2 , wherein Lis —C(O)— and Ris —ORor —(CH)R claim 2 , —OC-Calkyl-mono-C-Calkyl amino claim 2 , —OC-Calkyl-di-C-Calkyl amino claim 2 , —OC-Calkyl-N-heterocyclyl claim 2 , —C-Calkyl-mono-C-Calkyl amino claim 2 , —C-Calkyl-di-C-Calkyl amino claim 2 , or —C-Calkyl-N-heterocyclyl.4. The compound according to claim 2 , wherein claim 2 , Ris C-C-alkoxy-C-C-alkoxy.5. The compound according to claim 2 , wherein Ris methoxyethoxy.6. The compound according to claim 3 , wherein Lis —S(O)— claim 3 , and Ris —NRR claim 3 , —(CH)R claim 3 , —C-Calkyl-mono-C-Calkyl amino claim 3 , —C-Calkyl-di-C-Calkyl amino claim 3 , or —C-Calkyl-N-heterocyclyl.7. The compound according to claim 3 , wherein Lis —O—.8. The compound according to claim 7 , wherein claim 7 , Ris phenoxyphenyl wherein each phenyl is optionally substituted with one or two Rsubstituents. In a more specific example claim 7 , the Rsubstituents are halo.9. The compound according to claim 8 , wherein the saturated or mono- or poly-unsaturated C-C-mono- or fused poly-cyclic hydrocarbyl containing one or two annular heteroatoms per ring is selected from the group consisting of morpholinyl claim 8 , piperazinyl claim 8 , homopiperazinyl ...

Подробнее
13-06-2013 дата публикации

Benzotriazine Oxides as Drugs Targeting Mycobacterium Tuberculosis

Номер: US20130150369A1
Принадлежит: SRI INTERNATIONAL

Benzotriazine doxides are disclosed as drugs targeting , including novel compounds of formula I: 2. The compound of wherein:each X is independently H, halogen, alkyl, OR, SR, NR′R, or BR′R, wherein each R is independently H, halogen, or alkyl;W is N, C, O, S or B;each A and B is H or optionally substituted alkyl, which may be joined in an optionally hetero-, cycloalkyl; andZ is an optionally present, optionally substituted 4-8 membered ring, saturated or unsaturated, fused to the bezotriazine ring at either the 6,7-, 5,6- or 7,8-position.3. The compound of wherein:each X is independently H, halogen, alkyl, OR, SR, NR′R, or BR′R, wherein each R is independently H, halogen, or alkyl;W is N, C, O, S or B;each A and B is optionally substituted alkyl, which may be joined in an optionally hetero-, cycloalkyl; andZ is an optionally present, optionally substituted 4-8 membered ring, saturated or unsaturated, fused to the bezotriazine ring at either the 6,7-, 5,6- or 7,8-position.4. The compound of wherein:each X is independently H, halogen, alkyl, OR, SR, NR′R, or BR′R, wherein each R is independently H, halogen, or alkyl;W is N;each A and B is optionally substituted alkyl, which may be joined in a heterocycloalkyl; andZ is an optionally present, optionally substituted 5 or 6-membered ring, saturated or unsaturated, fused to the bezotriazine ring at the 7,8-position.5. The compound of wherein:each X is H;W is N;A and B are joined in an optionally substituted piperidinyl or pyrrolidinyl; andZ is a 5-membered ring, unsaturated, fused to the bezotriazine ring at the 7,8-position.9mycobacterium tuberculosis. A pharmaceutical composition or kit comprising a compound of and a second claim 1 , different anti-(Mtb) drug.10. A method of making a compound of comprising an oxidation reaction using HOF:ACN.11mycobacterium tuberculosis. A method of treating a (Mtb) infection claim 1 , comprising: contacting a person in need thereof with an effective amount of compound of . ...

Подробнее
13-06-2013 дата публикации

Tetrahydropyridinyl and Dihydropyrrolyl Compounds and the Use Thereof

Номер: US20130150377A1
Принадлежит:

The invention relates to tetrahydropyridinyl and dihydropyrrolyl compounds of Formula (I): and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X, Y, Z, R, R, m, and n are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain. 166.-. (canceled)68. The method of claim 67 , wherein the N-type calcium channel is modulated.6973.-. (canceled)74. The method of claim 67 , wherein n is 1.79. The method of claim 67 , wherein n is 0.84. The method of claim 67 , wherein Hy is selected from the group consisting of pyridyl claim 67 , pyrimidinyl claim 67 , pyrazinyl claim 67 , pyrrolyl claim 67 , imidazolyl claim 67 , triazolyl claim 67 , thiazolyl claim 67 , oxazolyl claim 67 , isoxazolyl claim 67 , and 1 claim 67 ,2 claim 67 ,4-oxadiazolyl.85. The method of claim 84 , wherein Hy is selected from the group consisting of pyridin-2-yl claim 84 , pyridin-3-yl claim 84 , pyrimidin-2-yl claim 84 , pyrimidin-4-yl claim 84 , pyrazin-2-yl claim 84 , imidazol-2-yl claim 84 , imidazol-4-yl claim 84 , and oxazol-2-yl.86. The method of claim 85 , wherein Hy is pyridin-2-yl claim 85 , pyridin-3-yl claim 85 , pyrimidin-2-yl claim 85 , or oxazol-2-yl.87. The method of claim 67 , wherein Ris attached to a carbon atom adjacent to a nitrogen atom of said Hy ring.91. The method of claim 88 , wherein X is —CHR— and Rand Rboth are hydrogen.92. The method of claim 88 , wherein X is —CHR— and Rand Rtogether form a bridge —(CH)— and p is 2 claim 88 , 3 claim 88 , or 4.93. The method of claim 92 , wherein p is 2.94. The method of claim 88 , wherein X is —C(═O)— and Ris hydrogen.95. The method of claim 67 , wherein Ris —C(═W)NRR claim 67 , wherein W is O or NR claim 67 , Ris hydrogen or alkyl claim 67 , and Rand Rare each independently ...

Подробнее
13-06-2013 дата публикации

NOVEL PYRIDINE DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS

Номер: US20130150411A1
Принадлежит: ALLERGAN, INC.

The present invention relates to novel pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. 3. A compound according to claim 1 , wherein:{'sup': '1', 'sub': 1-6', '1-6', '2, 'Ris H, halogen, —OCalkyl, Calkyl or NO;'}{'sup': '2', 'sub': 1-6', '1-6', '2, 'Ris H, halogen, —OCalkyl, Calkyl or NO;'}{'sup': '3', 'sub': 1-6', '1-6', '2, 'Ris H, halogen, —OCalkyl, Calkyl or NO;'}{'sup': '4', 'sub': '1-6', 'Ris H, halogen or Calkyl,'}{'sup': '5', 'sub': '1-6', 'Ris H, halogen or Calkyl;'}{'sup': '6', 'sub': '1-6', 'Ris H, halogen or —Calkyl;'}{'sub': '2', 'L is CH;'}{'sup': '7', 'sub': '1-6', 'Ris H, halogen or Calkyl; and'}{'sup': '8', 'sub': '1-6', 'Ris H, halogen or —Calkyl.'}{'sup': '14', 'sub': 1-6', '3-6, 'Ris H, Calkyl or Ccycloalkyl; and'}{'sup': '15', 'sub': 1-6', '3-6, 'Ris H, Calkyl or Ccycloalkyl.'}5. A compound according to claim 4 , wherein:{'sup': '1', 'sub': '2', 'Ris H, chloro, bromo, fluoro, methyl, ethyl, methoxy or —NO;'}{'sup': '2', 'Ris H, chloro, trifluoromethyl, methyl or methoxy;'}{'sup': '3', 'Ris H, fluoro or methyl;'}{'sup': '4', 'Ris H or methyl;'}{'sup': '5', 'Ris H, methyl, chloro or iso-butyl;'}{'sup': '6', 'Ris H, methyl or chloro;'}{'sup': '7', 'Ris H; and'}{'sup': '8', 'Ris H.'}6. A compound according to claim 1 , selected from:3-{5-[1-(5-chloropyridin-3-yl)-2-(3,4-dimethylphenyl)ethyl]-1,2,4-oxadiazol-3-yl}-N-methylpyridin-2-amine;3-{5-[1-(6-chloropyridin-3-yl)-2-(3,4-dimethylphenyl)ethyl]-1,2,4-oxadiazol-3-yl}-N-methylpyridin-2-amine;3-{5-[1-(6-chloropyridin-3-yl)-2-(3,5-dimethylphenyl)ethyl]-1,2,4-oxadiazol-3-yl}-N-methylpyridin-2-amine;N-methyl-3-(5-(1-(thiophen-3-yl)-2-(p-tolyl)ethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-amine;3-(5-(2-(3,4-dimethylphenyl)-1-(thiophen-3-yl)ethyl)-1,2,4-oxadiazol-3-yl)-N-methylpyridin-2-amine;N-methyl-3-(5-(1-(thiophen-2-yl)-2-(p-tolyl)ethyl)-1,2,4-oxadiazol-3-yl)pyridin-2-amine; and3 ...

Подробнее
13-06-2013 дата публикации

COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE

Номер: US20130150417A1
Принадлежит: ALLERGAN, INC.

The present invention provides compounds, that are N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfon-amido)propyl)benzyppyrrolidin-2-ypoxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals. The compound may be represented by the following formula wherein Ris selected from the group consisting of CORand CON(R)SORwherein R, R, R, R, and Rare as defined in the specification. The compounds may be administered to treat DP, FP, EP, EP, TP and/or EPreceptor mediated diseases or conditions. 1. A compound , that is a N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide wherein the 5 substituent is selected from the group consisting of halo and alkyloxy radicals.2. The compound of wherein said alkyl radical is a n-alkyl radical.3. The compound of wherein said n-alkyl radical comprises from 5 to 10 carbon atoms.4. The compound of wherein said n-alkyl radical is octyl.5. The compound of wherein said alkyl radical is a cycloalkyl radical.6. The compound of wherein said cycloalkyl radical is a cyclohexyl-n-alkyl radical.7. The compound of wherein said cyclohexyl-n-alkyl radical is cyclohexylbutyl.8. The compound of wherein the 5-substituent is selected from the group consisting of fluoro and chloro.9. The compound of wherein said alkyloxy is selected from the group consisting of methyloxy and dioxol.10. A compound claim 1 , that is selected from the group consisting of N-alkyl-2-(1-(5-substituted-2-(3-oxo-3-(trifluoromethylsulfonamido)propyl)benzyl)pyrrolidin-2-yl)oxazole-4-carboxamide claim 1 , 3-(2-{2R-[4-(4-alkylcarbamoyl)-oxazol-2-yl]-pyrrolidin-1-ylmethyl}-4-substituted-phenyl)-propionic acid and alkyl esters thereof claim 1 , wherein the substituent is selected from the group consisting of halo and alkyloxy radicals.11. The compound of wherein said compound is selected from the group consisting of(S)—N-(4-cyclohexylbutyl)-2-(1-(5-fluoro ...

Подробнее
20-06-2013 дата публикации

SUBSTITUTED 3-PHENYL-1,2,4-OXADIAZOLE COMPOUNDS

Номер: US20130158001A1
Принадлежит:

Disclosed are compounds of Formula (I): (I) or stereoisomers, salts, or prodrugs thereof, wherein: (i) R1 and R2 are independently C-Calkyl, or (ii) Rand Rtogether with the carbon atom to which they are attached, form a cyclic group; and Q is H, Calkyl, phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents, and G is defined herein. Also disclosed are method of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. There compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and chronic inflammatory disease. 4. The compound according to or a stereoisomer or a salt thereof claim 3 , wherein Ris —CHand Ris C-Calkyl.5. The compound according to or a stereoisomer or a salt thereof claim 3 , wherein Rand Rtogether with the carbon atom to which they are attached claim 3 , form a cyclic group selected from adamantanyl claim 3 , Ccycloalkyl claim 3 , and a 5- to 6-membered heterocycloalkyl claim 3 , wherein each of said cycloalkyl and heterocycloalkyl rings is substituted with zero to 4 R.6. The compound according to or a salt thereof claim 1 , wherein said compound is selected from 1-(4-(5-(2-(1-phenylcyclohexyl)ethyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)benzyl) azetidine-3-carboxylic acid (1); 1-(4-(5-(2-(2-oxo-1-phenylcyclohexyl)ethyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylic acid (2); 2-(2-(3-(4-((S)-2 claim 1 ,3-dihydroxypropoxy)-3 claim 1 ,5-dimethylphenyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-5-yl)ethyl)-2-(4-fluorophenyl)cyclohexanone (3); 2-(2-(3-(4-((S)-2 claim 1 ,3-dihydroxypropoxy)-3 claim 1 ,5-dimethylphenyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-5-yl)ethyl)-2-(4-fluorophenyl)cyclohexanone (4); 1-(4-(5-(2-(1-(3 claim 1 ,4-difluorophenyl)cyclohexyl)ethyl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)benzyl) azetidine-3-carboxylic acid ...

Подробнее
20-06-2013 дата публикации

AMINO ACID-, PEPTIDE-AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF

Номер: US20130158021A1
Принадлежит: Massachusetts Institute of Technology

Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: 2. (canceled)3. The compound of claim 1 , wherein each instance of Q is O.4. The compound of claim 1 , wherein at least one instance of Ris H.5. The compound of claim 1 , wherein Ris a group of formula (iv).6. The compound of claim 1 , wherein L is an optionally substituted alkylene.811-. (canceled)1534-. (canceled)3750-. (canceled)5359-. (canceled)61. (canceled)62. The composition of claim 60 , wherein the composition is a pharmaceutical composition claim 60 , a cosmetic composition claim 60 , a nutraceutical composition claim 60 , or a composition with non-medical application.6377-. (canceled)79. The method of claim 78 , wherein the desired property is solubility in water claim 78 , solubility at different pH claim 78 , ability to bind polynucleotides claim 78 , ability to bind heparin claim 78 , ability to bind small molecules claim 78 , ability to bind protein claim 78 , ability to form microparticles claim 78 , ability to increase transfection efficiency claim 78 , ability to support cell growth claim 78 , ability to support cell attachment claim 78 , ability to support tissue growth claim 78 , and/or intracellular delivery of the APPL and/or an agent complexed or attached thereto to aid in bioprocessing.81. The method of claim 80 , wherein the disease claim 80 , disorder claim 80 , or condition is selected from the group consisting of ...

Подробнее
04-07-2013 дата публикации

SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS

Номер: US20130172315A1
Принадлежит: ChemoCentryx, Inc.

Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer. 2. A compound of claim 1 , wherein X and Y are not both N.3. A compound of claim 1 , wherein Ris H claim 1 , and each Ris a member independently selected from the group consisting of Calkyl claim 1 , Chaloalkyl claim 1 , halogen and —CN.5. A compound of claim 4 , wherein X is C or CH.8. A compound of claim 7 , wherein n is 1 claim 7 , and Ris hydrogen or methyl.10. A compound of claim 9 , wherein n is 1 claim 9 , and Ris hydrogen or methyl.12. A compound of claim 11 , wherein n is 1 claim 11 , and Ris hydrogen or methyl.14. A compound of claim 1 , wherein B is C(O).15. A compound of claim 1 , wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidine and piperidine.16. A compound of claim 1 , wherein the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-2-yl and piperidin-2-yl claim 1 , and at least one of R claim 1 , Rand Ris other than hydrogen.17. A compound of claim 1 , wherein B is a bond.18. A compound of claim 1 , wherein B is a bond and the ring having Z as a ring vertex is selected from the group consisting of pyrrolidine claim 1 , piperidine and cyclohexane.19. A compound of claim 1 , wherein B is a bond and the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl claim 1 , pyrrolidin-2-yl claim 1 , piperidin-1-yl claim 1 , piperidin-2-yl claim 1 , piperidin-3-yl and cyclohexane.20. A compound of claim 1 , wherein B is a bond and the ring having Z as a ring vertex is selected from the group consisting of pyrrolidin-1-yl claim 1 , pyrrolidin-2-yl claim 1 , piperidin-1-yl claim 1 , piperidin-2-yl claim 1 , piperidin-3-yl and cyclohexane; and at least one of R claim 1 , Rand Ris other than hydrogen.21. A compound of claim 1 , wherein Z is CH or N.23. A pharmaceutical composition ...

Подробнее
04-07-2013 дата публикации

CHIRAL SYNTHESIS OF ISOXAZOLINES, ISOXAZOLINE COMPOUNDS, AND USES THEREOF

Номер: US20130172553A1
Принадлежит: CPSI STOCKHOLDER TRUST

Processes for the chiral syntheses of isoxazolines and intermediates are described. Compounds prepared thereby, and methods of using the compounds are also described. 6. The process of claim 5 , wherein the separating is carried out by a process comprising recrystallization claim 5 , chromatography claim 5 , or a combination thereof.9. The process of claim 8 , wherein the separating is carried out by a process comprising recrystallization claim 8 , chromatography claim 8 , or a combination thereof.11. The process of claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , R claim 1 , and Rare each independently hydrogen claim 1 , an alkyl group claim 1 , a cycloalkyl group claim 1 , an alkenyl group claim 1 , an alkynyl group claim 1 , an oxo group claim 1 , an aryl group claim 1 , a heterocyclic group claim 1 , a heteroaryl group claim 1 , an aralkyl group claim 1 , a heteroaralkyl group claim 1 , an amino group claim 1 , an alkylamino group claim 1 , a dialkylamino group claim 1 , an amidine group claim 1 , an amide group claim 1 , an alkylcarbonyl group claim 1 , an alkoxycarbonyl group claim 1 , an alkylaminocarbonyl group claim 1 , a dialkylamino carbonyl group claim 1 , an arylcarbonyl group claim 1 , an aryloxycarbonyl group claim 1 , an alkylsulfonyl group claim 1 , an arylsulfonyl group claim 1 , perhaloalkyl group claim 1 , a perhalocycloalkyl group claim 1 , a perhaloalkenyl group claim 1 , a perhaloalkynyl group claim 1 , a perhaloaryl group claim 1 , or a perhaloaralkyl group; wherein Rand Rmay be taken together to form a cyclic group; wherein Rand Rmay be taken together to form a cyclic group; wherein each group may be optionally and independently straight or branched; wherein each group may be optionally and independently substituted by one or more independent substituents; and wherein one or more than one atom in each group may be optionally and independently replaced with one or more independent heteroatoms.12. The process of claim 1 , wherein R claim ...

Подробнее
11-07-2013 дата публикации

ARYLETHYNYL DERIVATIVES

Номер: US20130178456A1
Принадлежит: Hoffmann-La Roche Inc.

The present invention relates to ethynyl compounds of formula I 2. The compound of claim 1 , selected from the group consisting of3-(3-fluoro-5-phenylethynyl-pyridin-2-yl)-5,5-dimethyl-oxazolidin-2-one;(5RS)-5-methoxymethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;(5R or 5S)-5-methoxymethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;(5S or 5R)-5-methoxymethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;5,5-dimethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;3-[5-(3-fluoro-phenylethynyl)-pyridin-2-yl]-5,5-dimethyl-oxazolidin-2-one;5,5-dimethyl-3-(5-pyridin-3-ylethynyl-pyridin-2-yl)-oxazolidin-2-one;(5RS)-5-tert-butyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;6-(5-phenylethynyl-pyridin-2-yl)-4-oxa-6-aza-spiro[2.4]heptan-5-one; and7-(5-phenylethynyl-pyridin-2-yl)-5-oxa-7-aza-spiro[3.4]octan-6-one.3. The compound of claim 1 , selected from the group consisting of3-(5-phenylethynyl-pyridin-2-yl)-1-oxa-3-aza-spiro[4.4]nonan-2-one;3-(5-phenylethynyl-pyridin-2-yl)-1-oxa-3-aza-spiro[4.5]decan-2-one;(5RS)-5-tert-butyl-5-methyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;(3aRS,6aSR)-3-(5-phenylethynyl-pyridin-2-yl)-hexahydro-cyclopentaoxazol-2-one;(3aRS,6aSR)-3-(5-pyridin-3-ylethynyl-pyridin-2-yl)-hexahydro-cyclopentaoxazol-2-one;(3aRS,6aSR)-3-[5-(5-fluoro-pyridin-3-ylethynyl)-pyridin-2-yl]-hexahydro-cyclopentaoxazol-2-one;(RS)-4,5,5-trimethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;4,4,5,5-tetramethyl-3-(5-phenylethynyl-pyridin-2-yl)-oxazolidin-2-one;3-[5-(5-fluoro-pyridin-3-ylethynyl)-pyridin-2-yl]-5,5-dimethyl-oxazolidin-2-one; and5,5-dimethyl-3-(5-pyrimidin-5-ylethynyl-pyridin-2-yl)-oxazolidin-2-one.4. The compound of claim 1 , selected from the group consisting of5,5-dimethyl-3-[5-(1-methyl-1H-pyrazol-4-ylethynyl)-pyridin-2-yl]-oxazolidin-2-one;3-[5-(4-fluoro-phenylethynyl)-pyridin-2-yl]-5,5-dimethyl-oxazolidin-2-one;3-[5-(3,4-difluoro-phenylethynyl)-pyridin-2-yl]-5,5-dimethyl-oxazolidin-2-one;3-[5-(2,5-difluoro- ...

Подробнее
11-07-2013 дата публикации

Cannabinoid receptor modulators

Номер: US20130178457A1
Принадлежит: Lupin Ltd

Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).

Подробнее
11-07-2013 дата публикации

ISOXAZOLE TREATMENTS FOR DIABETES

Номер: US20130178506A1

The present invention relates to compounds and methods for inducing synthesis and secretion of insulin from pancreatic beta cells. The methods may take place in vitro, ex vivo such as in isolates from adult mammalian tissue, or in vivo. Compounds and methods described herein may find use in the treatment of diabetes. 2. The method of claim 1 , wherein Ris a substituent of formula (A).3. The method of claim 2 , wherein G is S.4. The method of claim 3 , wherein R claim 3 , Ror Ris hydrogen.5. The method of claim 4 , wherein R claim 4 , Rand Rare each hydrogen.6. The method according to claim 1 , wherein Ris hydrogen.7. The method according to claim 1 , wherein Ris —NRR.8. The method of claim 7 , wherein Ror Ris cyclopropyl claim 7 , cyclobutyl claim 7 , cyclopentyl or cyclohexyl.9. The method of claim 8 , wherein Ror Ris cyclopropyl.11. The method of claim 10 , wherein G is S.12. The method of claim 11 , wherein R claim 11 , Ror Ris hydrogen.13. The method of claim 12 , wherein R claim 12 , Rand Rare each hydrogen.14. The method according to claim 1 , wherein Ris hydrogen.15. The method according to claim 1 , wherein Ris cyclopropyl or an aliphaticalcohol or an aliphaticpolyol.17. The method according to claim 1 , wherein said cell is located in an animal subject.18. The method according to claim 1 , wherein said cell is contacted ex vivo.2036-. (canceled)3852-. (canceled)5470-. (canceled)72. (canceled) This application claims benefit of priority to U.S. Provisional Application Ser. Nos. 61/563,419, filed Nov. 23, 2011, and 61/566,056, filed Dec. 2, 2011, the entire contents of both applications being incorporated by reference herein.The invention was made with government support under NIH P60 DK079626, R37 DK34128 and R01 DK55310 awarded by the National Institutes of Health. The government has certain rights in the invention.1. Field of the InventionThe present invention relates generally to the fields of cell biology, developmental biology and medicine. More ...

Подробнее
18-07-2013 дата публикации

FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS

Номер: US20130184255A1
Принадлежит: Gilead Sciences, Inc.

The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: 166.-. (canceled)67. A compound selected from the group consisting of:4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one;4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one;7-(4-chlorophenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one;7-(4-tert-butylphenyl)-4-(pyrimidin-2-ylmethyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; and4-(imidazo[1,2-a]pyridin-2-ylmethyl)-7-(4-(trifluoromethyl)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one;or a pharmaceutically acceptable salt thereof.73. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of or a pharmaceutically acceptable salt thereof.74. A method of treating a disease state in a mammal that is alleviable by treatment with an agent capable of reducing late sodium current claim 67 , comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of or a pharmaceutically acceptable salt thereof.75. The method of claim 74 , wherein the disease state is a cardiovascular disease selected from one or more of atrial arrhythmias claim 74 , ventricular arrhythmias claim 74 , heart failure (including congestive heart failure claim 74 , diastolic heart failure claim 74 , systolic heart failure claim 74 , acute heart failure) claim 74 , Prinzmetal's (variant) angina claim 74 , stable angina claim 74 , unstable angina claim 74 , exercise induced angina claim 74 , congestive heart disease claim 74 , ischemia claim 74 , recurrent ischemia claim 74 , reperfusion injury claim 74 , myocardial infarction claim 74 , acute coronary syndrome ...

Подробнее
18-07-2013 дата публикации

Methods for Treating Parkinson's Disease Using Pro-Neurogenic Compounds

Номер: US20130184271A1

This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or protecting neuronal cell from cell death. Various compounds are disclosed herein. In vivo activity tests suggest that these compounds may have therapeutic benefits in neuropsychiatric and/or neurodegenerative diseases such as schizophrenia, major depression, bipolar disorder, normal aging, epilepsy, traumatic brain injury, post-traumatic stress disorder, Parkinson's disease, Alzheimer's disease, Down syndrome, spinocerebellar ataxia, amyotrophic lateral sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of a neuro-active drug, retinal degeneration, spinal cord injury, peripheral nerve injury, physiological weight loss associated with various conditions, as well as cognitive decline associated with normal aging, chemotherapy, and the like. 2. The method of claim 1 , wherein when A is CRR claim 1 , the carbon attached to Rand Ris substituted with four different substituents claim 1 , and is (R) or (S) configured.3. The method of claim 2 , wherein the compound or salt is (+) (dextrorotatory) or (−) (levororotatory).4. The method of claim 1 , wherein the effective amount of the compound or salt stimulates neurogenesis.5. The method of claim 1 , wherein the effective amount of the compound or salt reduces neuron cell death.6. The method of claim 1 , wherein the compound is selected from:R-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;S-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-iminopyridin-[(2H)-yl)propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylthio)propan-2-ol;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(3-methoxyphenyl)acetamide;5-((3,6-dibromo-9H-carbazol-9-yl)methyl)-3-(3-methoxyphenyl)-oxazolidin-2-one;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2- ...

Подробнее
18-07-2013 дата публикации

Methods of Treating Traumatic Brain Injury Using Pro-Neurogenic Compounds

Номер: US20130184300A1

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death. 2. The method of claim 1 , wherein when A is CRR claim 1 , the carbon attached to Rand Ris substituted with four different substituents claim 1 , and is (R) or (S) configured.3. The method of claim 2 , wherein the compound or salt is (+) (dextrorotatory) or (−) (levororotatory).4. The method of claim 1 , wherein the effective amount of the compound or salt stimulates neurogenesis.5. The method of claim 1 , wherein the effective amount of the compound or salt reduces neuron cell death.6. The method of claim 1 , wherein the compound is selected from:R-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;S-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-iminopyridin-1(2H)-yl)propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylthio)propan-2-ol;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(3-methoxyphenyl)acetamide;5-((3,6-dibromo-9H-carbazol-9-yl)methyl)-3-(3-methoxyphenyl)-oxazolidin-2-one;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-one;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-methoxypropyl)-3-methoxyaniline;1-(3,6-Dimethyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;1-(3-Bromo-6-methyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;1-(3,6-Dichloro-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;1-(5-bromo-2,3-dimethyl-1H-indol-1-yl)-3-(phenylamino)propan-2-ol;1-(3,6-Dibromo-9H-pyrido[3,4-b]indol-9-yl)-3-(phenylamino)propan-2-ol;1-(3-Azidophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;1,3-Bis(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;1-(9H-Carbazol-9-yl)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxy-N-(3-methoxyphenyl)-propanamide;Ethyl 5-(2-Hydroxy- ...

Подробнее
18-07-2013 дата публикации

Methods of Treating Post-Traumatic Stress Disorder Using Pro-Neurogenic Compounds

Номер: US20130184301A1

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death. 2. The method of claim 1 , wherein when A is CRR claim 1 , the carbon attached to Rand Ris substituted with four different substituents claim 1 , and is (R) or (S) configured.3. The method of claim 2 , wherein the compound or salt is (+) (dextrorotatory) or (−) (levororotatory).4. The method of claim 1 , wherein the effective amount of the compound or salt stimulates neurogenesis.5. The method of claim 1 , wherein the effective amount of the compound or salt reduces neuron cell death.6. The method of claim 1 , wherein the compound is selected from:R-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;S-1-(3,6-Dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(2-iminopyridin-1(2H)-yl)propan-2-ol;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(phenylthio)propan-2-ol;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-hydroxypropyl)-N-(3-methoxyphenyl)acetamide;5-((3,6-dibromo-9H-carbazol-9-yl)methyl)-3-(3-methoxyphenyl)-oxazolidin-2-one;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline;1-(3,6-dibromo-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-one;N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-methoxypropyl)-3-methoxyaniline;1-(3,6-Dimethyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;1-(3-Bromo-6-methyl-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)-propan-2-ol;1-(3,6-Dichloro-9H-carbazol-9-yl)-3-(3-methoxyphenylamino)propan-2-ol;1-(5-bromo-2,3-dimethyl-1H-indol-1-yl)-3-(phenylamino)propan-2-ol;1-(3,6-Dibromo-9H-pyrido[3,4-b]indol-9-yl)-3-(phenylamino)propan-2-ol;1-(3-Azidophenylamino)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;1,3-Bis(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;1-(9H-Carbazol-9-yl)-3-(3,6-dibromo-9H-carbazol-9-yl)propan-2-ol;3-(3,6-Dibromo-9H-carbazol-9-yl)-2-hydroxy-N-(3-methoxyphenyl)-propanamide;Ethyl 5-(2-Hydroxy- ...

Подробнее
18-07-2013 дата публикации

PROCESS AND COMPOSITION OF MAKING POLYMERIZABLE RESINS CONTAINING OXAZOLIDONE

Номер: US20130184467A1
Автор: JIN XIAOMING
Принадлежит: DENTSPLY INTERNATIONAL INC.

Disclosed herein are a process and composition to make polymerizable resins containing oxazolidone, in which organic acid-catalyzed and/or thermal annealing process got involved and consequently promoted a unique intramolecular transformation from a linear urethane linkage to a cyclic urethane linkage for those specifically constructed urethane resins containing α-substituted β-ketone moieties. 1. A process , comprising:reacting at least two isocyanates and an α-substituted β-ketone to form a linear condensate,converting the linear condensate into a cyclic oxazolidone based resin or polymer,wherein converting the linear condensate is induced by thermally annealing the linear condensate at a temperature of from about 25° C. to about 150° C., or by reacting the linear condensate in the presence of an acid at a temperature of from about 23° C. to about 27° C.4. The process according to claim 1 , wherein the linear condensate includes a linear urethane linkage.5. The process according to claim 1 , wherein the linear condensate includes polymerizable groups that remain intact even after the linear condensate is converted into the cyclic oxazolidone based resin or polymer.6. The process according to claim 5 , wherein the polymerizable groups are acrylate claim 5 , methacrylate claim 5 , vinyl or combinations thereof.7. The process according to claim 1 , wherein the amount of acid present during converting the linear condensate into the cyclic oxazolidone based resin or polymer is from about 0.1 weight percent to about 5 weight percent of the resin or polymer.8. The process according to claim 1 , wherein the acid is an organic acid or an inorganic acid.9. The process according to claim 8 , wherein the organic acid is a carboxylic acid claim 8 , a sulfonic acids claim 8 , a compound having a thiol group claim 8 , a compound having an enol group claim 8 , or methacrylic acid.10. The process according to claim 9 , wherein the organic acid is formic acid claim 9 , acetic acid ...

Подробнее
25-07-2013 дата публикации

NOVEL DOSAGE FORMULATION

Номер: US20130189362A1
Принадлежит: Hoffmann-La Roche Inc.

The invention relates to a process for preparing a pharmaceutical tablet composition which comprises an active pharmaceutical ingredient of formula I 1. A process for preparing a pharmaceutical composition comprising1) blending an active pharmaceutical ingredient and a water soluble poloxamer to form a powder blend;2) extruding the powder blend form step 1) to form a hot melt extrudate;3) passing the hot melt extrudate through a sieving machine to obtain milled material, whereby more than one sieving step may be necessary to obtain material in the desired particle size range;4) blending the milled extrudate from step 3) with a filler(s) and a disintegrant;5) blending the mixture from step 4) with a processing aid and a glidant; and6) compressing the final blend prepared in step 5) into tablets.3. The process of claim 2 , wherein the water soluble poloxamer is poloxamer 188.4. The process of claim 2 , wherein the compound of formula I is 2-(3 claim 2 ,5-bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramidehydrochloride.5. The process of claim 4 , wherein the water soluble poloxamer is poloxamer 188.6. The process of claim 1 , which comprises1) placing about 50% of the active pharmaceutical ingredient/drug substance is placed in a blender, e.g. PK, Bin or Bohle mixer,2) adding the water soluble poloxamer, followed by the remainder of the drug substance,3) mixing the material from step 2) for about 30 minutes to form a powder blend,4) transferring the powder blend from step 3) into a hot melt extruder (e.g. Leistritz) using a hopper-feeder (e.g. K-Tron Soder)5) extruding the powder blend through the hot melt extruder,6) collecting the hot melt extrudate at room temperature,7) passing the hot melt extrudate through a sieving machine, e.g. FitzMill, on a first pass set using slow speed knives forward through a #3 screen and then a second pass at medium speed knives forward through a #2 screen,8) placing about 50% of the milled ...

Подробнее
25-07-2013 дата публикации

FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF

Номер: US20130190271A1
Принадлежит: Sumitomo Chemical Company, Limited

Disclosed is a harmful arthropod control composition comprising, as an active ingredient, a fused heterocyclic compound represented by formula (1) [wherein Aand Aindependently represent a nitrogen atom or the like; Rand Rindependently represent a halogen atom or the like; Rand Rindependently represent a halogen atom or the like; Rand Rindependently represent a linear C1-C6 hydrocarbon group which may be substituted, or the like (provided that both Rand Rcannot represent a hydrogen atom simultaneously); and n represents 0 or 1]. The harmful arthropod control composition has an excellent efficacy to control harmful arthropods. 2. The arthropod pest control composition according to claim 1 , wherein in the compound{'sup': 2', '3', '8', '8', '9', '8', '9', '8', '10', '8', '9', '10', '11', '12, 'sub': m', '2, 'each of Rand Rindependently represents a C1-C6 acyclic hydrocarbon group optionally substituted with one or more members selected from Group X; a C3-C6 alicyclic hydrocarbon group optionally substituted with one or more members selected from Group X; a phenyl group optionally substituted with one or more members selected from Group Y; a benzyl group optionally substituted with one or more members selected from Group Y; a 5- or 6-membered heterocyclic group optionally substituted with one or more members selected from Group Y; —OR; —NRR; —NRC(O)R; —S(O)R; —COR; —CONRR; —CONRNRR; a cyano group; a nitro group; a halogen atom; or a hydrogen atom; and'}{'sup': 8', '9, 'each of Rand Rindependently represents a C1-C6 acyclic hydrocarbon group optionally substituted with one or more members selected from Group X; a C3-C6 alicyclic hydrocarbon group optionally substituted with one or more members selected from Group X; a phenyl group optionally substituted with one or more members selected from Group Y; a 5- or 6-membered heterocyclic group optionally substituted with one or more members selected from Group Y; or a hydrogen atom.'}3. The arthropod pest control composition ...

Подробнее
25-07-2013 дата публикации

Pro-Neurogenic Compounds

Номер: US20130190339A1

This invention relates generally to stimulating neurogenesis (e.g., post-natal neurogenesis, e.g., post-natal hippocampal neurogenesis) and protecting from neuron cell death. 2. The compound or salt of claim 1 , wherein A is:{'sup': A1', 'A2', 'A1', 'A2', '9', '9, 'sub': 1', '3', '1', '3', '1', '3, '(i) CRR, wherein each of Rand Ris independently selected from hydrogen, halo, C-Calkyl, and OR, wherein Ris hydrogen or C-Calkyl that is optionally substituted with hydroxyl or C-Calkoxy; or'}(ii) C═O.3. The compound or salt of claim 1 , wherein A is CRR claim 1 , wherein each of Rand Ris claim 1 , independently claim 1 , hydrogen claim 1 , halo claim 1 , C-Calkyl claim 1 , or OR.4. The compound or salt of claim 3 , wherein one of Rand Ris independently selected from hydrogen claim 3 , halo claim 3 , C-Calkyl claim 3 , and OR; and the other of Rand Ris independently selected from halo claim 3 , C-Calkyl claim 3 , and OR.5. The compound or salt of claim 4 , wherein one of Rand Ris halo claim 4 , and the other of Rand Ris hydrogen claim 4 , halo claim 4 , or C-Calkyl.6. The compound or salt of claim 5 , wherein one of Rand Ris fluoro claim 5 , and the other of Rand Ris hydrogen or fluoro.7. The compound or salt of claim 3 , wherein one of Rand Ris OR; and the other of Rand Ris C-Calkyl.8. The compound or salt of claim 7 , wherein one of Rand Ris OH; and the other of Rand Ris CH.9. The compound or salt of claim 3 , wherein the carbon attached to Rand Ris substituted with four different substituents claim 3 , and is (R) or (S) configured.10. The compound or salt of claim 9 , wherein the formula (I) compound is (+) (dextrorotatory) or (−) (levororotatory).11. The compound or salt of claim 1 , wherein Ris selected from halo claim 1 , hydroxyl claim 1 , sulfhydryl claim 1 , C-Calkoxy claim 1 , C-Cthioalkoxy claim 1 , C-Chaloalkoxy claim 1 , C-Cthiohaloalkoxy claim 1 , C-Calkyl claim 1 , C-Chaloalkyl claim 1 , C-Calkynyl claim 1 , cyclopropyl claim 1 , —N claim 1 , cyano claim 1 ...

Подробнее
25-07-2013 дата публикации

SUBSTITUTED OXADIAZOLE COMPOUNDS

Номер: US20130190361A1
Принадлежит: BRISTOL-MYERS SQUIBB COMPANY

Disclosed are compounds of Formula (I): 2. The compound according to or stereoisomers claim 1 , N-oxides claim 1 , or salts thereof; wherein:Ring A is phenyl or 5- to 6-membered heteroaryl having at least one N or S heteroatom;{'sub': 1', '2', '1-3, '(i) Rand Rare independently Calkyl; or'}{'sub': 1', '2', '3-7', 'a, '(ii) Rand Rtogether with the carbon atom to which they are attached, form a cyclic group selected from Ccycloalkyl and 4- to 6-membered heterocycloalkyl, wherein each of said cycloalkyl and heterocycloalkyl rings is substituted with zero to 4 R;'}{'sub': '3', 'claim-text': [{'sub': 1-4', '3', '1-3', '3', 'm', '1-2', '2, '(i) F, Cl, Calkyl, —CF, —O(Calkyl), —OCF, —S(O)(Calkyl), and/or —NH; and/or'}, {'sub': 2', '1', '1', '2', '1', '2', '1', '2', '2', '1', '1', '2', '1-3', '3', '1-2, '(ii) —CHA, —OA, —OCHA, —CHOA, and/or —CHSOA, wherein Ais phenyl, pyridinyl, thiazolyl, or imidazolyl substituted with zero to 2 substituents independently selected from F, Cl, —NH, Calkyl, —CF, and/or Calkoxy;'}], 'each Ris independently{'sub': '1', 'claim-text': [{'sub': b', 'b', '2-4, '(a) —(CRR)—,'}, {'sub': 2', '0-2', 'c', 'c', '2', '0-2, '(b) —(CH)—CR═CR—(CH), or'}, {'sub': 2', '0-2', '2', '1-2, '(c) —(CH))(CH)—;'}], 'Lis{'sub': '2', 'claim-text': (a) a bond,', {'sub': b', 'b', '1-4, '(b) —(CRR),'}, {'sub': 2', '0-2', 'c', 'c', '2', '0-2, '(c) —(CH)—CR═CR—(CH), or'}, {'sub': 2', '0-2', '2', '1-2, '(d) —(CH)O(CH)—;'}], 'Lis{'sub': 1-3', '2', '2', '3', '1-2', '3, 'Q is phenyl or 5- to 6-membered heteroaryl substituted with zero to 3 substituents independently selected from F, Cl, Calkyl, —CN, —NO, —NH, —CF, Calkoxy, and/or —OCF;'}{'sub': a', '3', 'a, 'each Ris independently F, Cl, and/or —CH; and/or two Rattached to the same carbon atom form ═O;'}{'sub': b', '3', '1-2', 'b', 'b, 'each Ris independently H, —CH, F, —OH, and/or Calkoxy, provided that if one Ris —OH, then the second Rattached to the same carbon is not —OH or F; and'}{'sub': c', '3, 'each Ris independently H, ...

Подробнее
25-07-2013 дата публикации

PROCESSES FOR THE PREPARATION OF 4'-[3-[4-(6-FLUORO-1,2-BENZISOXAZOL-3-YL)PIPERIDINO]PROPOXY]-3'-METHOXYACETOPHENONE AND INTERMEDIATES THEREOF

Номер: US20130190501A1
Принадлежит: SYMED LABS LIMITED

The present invention relates to processes for the preparation of 4′-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof. The present invention also provides a process for purifying 4′-[3-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone to obtain the purity greater than about 98.0 area % to about 99.0 area % as measured by HPLC, preferably greater than about 99.0 area % to about 99.5 area %, more preferably greater about 99.5 area % to about 99.9 area %. individual impurities lower than about 0.15 area %, preferably lower than about 0.1% and total impurities lower than about 0.5 area % by HPLC. 130-. (canceled)32. A process of claim 31 , wherein the oxidizing agent is selected from the group consisting of collin's reagent claim 31 , pyridinium dichromate claim 31 , pyridinium chlorochromate claim 31 , pyridinium chlorochromate on alumina claim 31 , DMSO-DCC claim 31 , DMSO-acetic anhydride or mixtures thereof claim 31 , preferably DMSO-DCC or DMSO-acetic anhydride.33. A process of claim 31 , wherein the solvent used optionally is selected from the group consisting of water claim 31 , halogenated solvents like dichloromethane claim 31 , ethylene dichloride claim 31 , chloroform claim 31 , chlorobenzene claim 31 , esters like ethyl acetate claim 31 , isopropyl acetate claim 31 , tertiary butyl acetate hydrocarbon solvents like n-heptane claim 31 , cyclohexane claim 31 , n-hexane claim 31 , toluene claim 31 , xylene claim 31 , ethers like tetrahydrofuran claim 31 , 1 claim 31 ,4-dioxane claim 31 , aprotic polar solvents like N claim 31 ,N-dimethylformamide (DMF) claim 31 , dimethylsulfoxide (DMSO) claim 31 , N claim 31 ,N-dimethylacetamide (DMA) claim 31 , N-methyl pyrrlolidine (NMP) or mixtures thereof claim 31 , preferably water or halogenated solvent.34. The process of claim 31 , wherein the reaction is carried out optionally in the presence of an acid.36. A process of claim 35 , ...

Подробнее
01-08-2013 дата публикации

MORPHOLINO SUBSTITUTED UREA DERIVATIVES AS MTOR INHIBITORS

Номер: US20130196982A1
Принадлежит:

The invention relates to compounds of formula (I) 2. A compound of claim 1 , wherein Ris H; or Calkyl claim 1 , wherein Calkyl is optionally substituted with one or more R claim 1 , which are the same or different; or Ccycloalkyl claim 1 , wherein Ccycloalkyl is optionally substituted with one or more Rya claim 1 , which are the same or different.3. A compound of claim 1 , wherein Ris halogen; CN; OR; C(O)N(RR); or N(RR).4. A compound of claim 1 , wherein Ris halogen; CN; OR; or N(RR).5. A compound of claim 1 , wherein Ris halogen; CN; OR; N(RR); or Calkyl claim 1 , wherein Calkyl is optionally substituted with one or more halogen claim 1 , which are the same or different.6. A compound of claim 1 , wherein Ris T.7. A compound of claim 1 , wherein Tis unsubstituted or substituted with 1 or 2 R claim 1 , which are the same or different.8. A compound of claim 1 , wherein Ris halogen; CN; S(O)R; S(O)R; N(R)SOR; SON(RR); N(R)C(O)R; C(O)N(RR); CO(O)R; or CHR.9. A compound of claim 1 , wherein Ris H.10. A compound of claim 1 , wherein Ris methyl.11. A compound of claim 1 , wherein n is 0; n is 1 and Ris methyl; or n is 2 and the two Rare joined together with the morpholine ring to form an 8-oxa-3-azabicyclo[3.2.1]octan-3-yl ring.12. A compound of claim 1 , wherein Ris F.13. A compound of claim 1 , wherein m claim 1 , n are independently selected from the group consisting of 0; and 1.14. A compound of claim 1 , wherein Xis N.15. A compound of claim 1 , wherein Ris H.16. A compound of selected from the group consisting of1-cyclopropyl-3-(4-(2-morpholino-6-(pyridin-3-yl)pyrimidin-4-yl)phenyl)urea;(S)-1-ethyl-3-(4-(6-(5-fluoro-2-(methylsulfonyl)phenyl)-2-(3-methylmorpholino)pyrimidin-4-yl)phenyl)urea;(S)-1-cyclopropyl-3-(4-(4-(3-methylmorpholino)-6-(pyridin-3-yl)pyrimidin-2-yl)phenyl)urea;(S)-1-cyclopropyl-3-(4-(2-(3-methylmorpholino)-6-(2-(methylsulfonyl)phenyl)pyrimidin-4-yl)phenyl)urea;(S)-1-cyclopropyl-3-(4-(6-(3-methylmorpholino)-2-(3-(methylsulfonyl)phenyl)pyrimidin-4-yl ...

Подробнее
01-08-2013 дата публикации

N-heteroaryl compounds

Номер: US20130196993A1
Принадлежит: Individual

This invention relates to certain N-heteroaryl compounds that are generally useful as medicaments, more specifically as medicaments for animals. The medicament can preferably be used for the treatment of helminth infections and the treatment of parasitosis, such as caused by helminth infections. This invention also relates to uses of the compounds to make medicaments and treatments comprising the administration of the compounds to animals in need of the treatments. This invention also relates to novel N-heteroaryl compounds and the preparation of said compounds. Moreover this invention relates to pharmaceutical compositions and kits comprising the compounds.

Подробнее
01-08-2013 дата публикации

Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament

Номер: US20130197011A1
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Substituted phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones which are glycine transporter-1 (GlyT1) inhibitors. These are useful for the treatment of schizophrenia, Alzheimer's Disease and other neurological and psychiatric disorders. 2. A compound according to claim 1 , wherein{'sup': '1', 'Ris a 5 or 6 membered moncyclic heteroaryl, having 1, 2 or 3 heteroatoms independently selected from the group consisting of O, N or S,'}{'sub': 1-2', '1-2', '1-2', '1-2, 'wherein said heteroaryl is optionally substituted with 1 or more substituents independently selected from the group consisting of C-alkyl-, C-alkyl-O—, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, cyclopropyl-, cyclobutyl-, cyclopropyl-O— and cyclobutyl-O— and in case a substituent is attached to a nitrogen ring atom said substituent is selected from the group consisting of C-alkyl- and C-alkyl-CO—,'}{'sub': 1-2', '1-2', '1-2', '3', '2', '2, 'and wherein each of said C-alkyl-, C-alkyl-O—, C-alkyl-CO—, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, cyclopropyl-, cyclobutyl, cyclopropyl-O— or cyclobutyl-Osubstituents may be substituted with 1 or more substituents independently selected from the group consisting of fluoro, —CF, —CHF, —CHF and —CN;'}{'sup': '2', 'Ris selected from the group consisting of hydrogen, methyl, ethyl, methoxy, ethoxy, —CN and cyclopropyl-,'}{'sub': 3', '2', '2, 'wherein each of said groups may be optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of fluoro, —CF, —CHF, —CHF and —CN;'}{'sup': '3', 'sub': 1-6', '1-6', '3', '2', '2', '1-4', '1-6, 'Ris as is selected from the group consisting of C-alkyl-O—, oxetanyl-O—, tetrahydrofuranyl-O—, tetrahydropyranyl-O— wherein said C-alkyl-O—, oxetanyl-O—, tetrahydrofuranyl-O—, tetrahydropyranyl-O— may be optionally substituted with 1, 2 or 3 substituents independently selected from the group consisting of fluoro, —CF, —CHF, —CHF, —CN, C-alkyl- and C-alkyl-O—;'}{'sup': '4', 'Ris hydrogen;'}{'sup': ...

Подробнее
08-08-2013 дата публикации

CAPROLACTAM MGLUR5 RECEPTOR MODULATORS

Номер: US20130203735A1
Принадлежит:

The present invention is directed to caprolactams which are positive allosteric modulators of metabotropic glutamate receptors, particularly the mGluR5 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved. 4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ais selected from the group consisting of: phenyl claim 1 , pyridyl and pyrrolyl.5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Ais selected from the group consisting of: phenyl and pyridyl.6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein R claim 1 , Rand Rare independently selected from the group consisting of:(1) hydrogen,(2) halogen,(3) hydroxyl,{'sub': '1-6', '(4) Calkyl, which is unsubstituted or substituted with halogen, hydroxyl, phenyl or napthyl,'}{'sub': '1-6', '(5) —O—Calkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,'}{'sub': 1-6', '1-6', '2, '(6) heteroaryl, wherein heteroaryl is selected from pyrrolyl, imidazolyl, indolyl, pyridyl, and pyrimidinyl, which is unsubstituted or substituted with halogen, hydroxyl, Calkyl, —O—Calkyl or —NO,'}{'sub': 1-6', '1-6', '2, '(7) phenyl, which is unsubstituted or substituted with halogen, hydroxyl, Calkyl, —O—Calkyl or —NO,'}{'sub': 1-6', '1-6', '2, '(8) —O-phenyl, which is unsubstituted or substituted with halogen, hydroxyl, Calkyl, —O—Calkyl or —NO, and'}{'sub': 1-6', '1-6', '1-6', '1-6', '1-6, '(9) —NH—Calkyl, or —N(Calkyl)(Calkyl), which is unsubstituted or substituted with halogen, hydroxyl, Calkyl, or —O—Calkyl ...

Подробнее
08-08-2013 дата публикации

Novel Inhibitors of LYN Kinase

Номер: US20130203817A1
Принадлежит: VASSA INFORMATICS

The invention includes novel compounds that inhibit LYN kinase activity. The invention further includes a method of treating, ameliorating or preventing cancer in a subject in need thereof, wherein the cancer is dependent on LYN kinase activity. 2. The compound of claim 1 , wherein Rand Rare independently unsubstituted or substituted aryl claim 1 , or unsubstituted or substituted heteroaryl.3. The compound of claim 1 , wherein Ris an electron pair claim 1 , Ris O; Ris CH or N; bonds ‘b’ and ‘e’ are double bonds claim 1 , and bonds ‘a’ claim 1 , ‘c’ and ‘d’ are single bonds.4. The compound of claim 1 , wherein Ris an electron pair claim 1 , Ris CH or N; Ris O; bonds ‘a’ and ‘c’ are double bonds claim 1 , and bonds ‘b’ claim 1 , ‘d’ and ‘e’ are single bonds.5. The compound of claim 1 , wherein Ris —CHCH— and Ris a chemical bond.8. The method of claim 6 , wherein the subject is human.11. The method of claim 9 , wherein the subject is human.12. The method of claim 9 , wherein the cancer is selected from the group consisting of CML claim 9 , B-CLL claim 9 , glioblastoma claim 9 , breast cancer claim 9 , Ewing's sarcoma and prostate cancer.13. The method of claim 12 , wherein the CML cancer is resistant to 4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide (imatinib). The present application claims the benefit of U.S. Provisional Patent Application No. 61/596,410, filed Feb. 8, 2012, which application is hereby incorporated by reference in its entirety herein.LYN kinase (protein sequence SEQ ID NO:1) is a member of the Src family of protein tyrosine kinases, and is mainly expressed in hematopoietic cells and in neural tissues (Yamanashi et al., 1989, Proc. Natl. Acad. Sci. U.S.A. 86(17):6538-42; Umemori et al., 1992, Brain Res. Mol. Brain. Res. 16(3-4): 303-10).In various hematopoietic cells, LYN kinase has emerged as a key enzyme involved in the regulation of cell activation. In these cells, a small amount of LYN kinase ...

Подробнее
15-08-2013 дата публикации

NANOSTRUCTURED APREPITANT COMPOSITIONS, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Номер: US20130209521A1
Принадлежит:

The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting. 18-. (canceled)9. A stable nanostructured Aprepitant composition comprising:(a) nanostructured Aprepitant having an average particle size of less than about 200 nm;(b) at least one stabilizer;wherein the composition is prepared in a continuous flow reactor.10. A stable nanostructured Aprepitant composition according to wherein the composition is prepared in a microfluidic based continuous flow reactor.11. A stable nanostructured Aprepitant composition according to further comprising an additional stabilizer for steric and electrostatical stabilization.12. The composition according to claim 9 , wherein the stabilizer is selected from the group of non-ionic claim 9 , anionic claim 9 , cationic polymers/surfactants claim 9 , and zwitterionic surfactants claim 9 , or combinations thereof.13. The composition according to wherein the stabilizer is selected from the group of cellulose and its derivatives claim 9 , polyvinylpyrrolidone claim 9 , graft copolymer comprised of polyethylene claim 9 , glycol claim 9 , polyvinylcaprolactam and polyvinylacetate (e.g. ...

Подробнее
15-08-2013 дата публикации

TETRAZOLE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS

Номер: US20130210796A1
Принадлежит:

The present invention relates to novel tetrazole compounds; to processes for their preparation; to pharmaceutical compositions containing the compounds; and to the use of the compounds in therapy to treat diseases for which blocking the Ca2.2 calcium channels is beneficial. Formula (I) wherein A is: (II) or (III) 3. A compound or salt according to claim 1 , wherein{'sup': 6', '7', '6', '7, 'sub': 1-5', '3-6, 'Ris hydrogen and Ris Calkyl or Ccycloalkyl; or Rand Rtogether with the nitrogen atom to which they are attached forms a saturated ring system B, where B is selected from'}a) a 4 to 7 membered monocyclic heterocyclic ring,b) a 5 to 10 membered fused bicyclic ring system;c) a bridged 4 to 7 membered monocyclic heterocyclic ring system; and{'sub': 1-3', '2', '1-3', '1-3, 'd) a 7 to 11 membered spiro ring system; which ring system B is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, oxo, Calkyl, cyano, —SO—Calkyl and Chaloalkyl;'}with the proviso that the compound is not4-{5-[(3,4-dimethyl-1-piperazinyl)methyl]-1H-tetrazol-1-yl}benzonitrile dihydrochloride;4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1H-tetrazol-1-yl)benzonitrile dihydrochloride; or4-{5-[(4-methyl-1-piperazinyl)methyl]-1H-tetrazol-1-yl}benzonitrile dihydrochloride.4. A compound or salt according to claim 1 , wherein{'sup': 6', '7, 'Rand Rtogether with the nitrogen atom to which they are attached forms a saturated ring system B, where B is selected from'}a) a 4 to 7 membered monocyclic heterocyclic ring,b) a 5 to 10 membered fused bicyclic ring system;c) a bridged 4 to 7 membered monocyclic heterocyclic ring system; andd) a 7 to 11 membered spiro ring system;{'sub': 1-3', '2', '1-3', '1-3, 'which ring system B is unsubstituted or substituted with 1 to 3 substituents independently selected from halogen, oxo, Calkyl, cyano, —SO—Calkyl and Chaloalkyl.'}5. A compound or salt according to claim 1 , wherein{'sup': 6', '7, 'Rand Rtogether with the nitrogen atom ...

Подробнее
22-08-2013 дата публикации

COMPOSITIONS AND METHODS FOR CONTROLLING NEMATODES

Номер: US20130217570A1
Принадлежит: MONSANTO TECHNOLOGY LLC

Compositions and processes for controlling nematodes are described herein, e.g., nematodes that infest plants or animals. The compounds include oxazoles, oxadiazoles and thiadiazoles. 167-. (canceled)70. A composition comprising the compound of in an aqueous carrier.71. The composition of wherein the composition comprises a surfactant.72. The composition of wherein the composition comprises a co-solvent.73. The composition of wherein the composition includes one or more of: a fungicide claim 70 , a herbicide claim 70 , and a pesticide.74. A method for control of unwanted nematodes claim 68 , the method comprising administering to mammals claim 68 , birds claim 68 , or their food claim 68 , plants claim 68 , seeds or soil a composition comprising an effective amount of a compound of .75. The method of wherein the composition comprises a surfactant.76. The method of wherein the composition comprises a co-solvent.77. The method of wherein the composition includes one or more of: a fungicide claim 74 , a herbicide claim 74 , and a pesticide.78. The method of wherein the composition is administered to a seed.79. A coated seed wherein the coating comprises a compound of .82. A composition comprising the compound of in an aqueous carrier.83. The composition of wherein the composition comprises a surfactant.84. The composition of wherein the composition comprises a co-solvent.85. The composition of wherein the composition includes one or more of: a fungicide claim 82 , a herbicide claim 82 , and a pesticide.86. A method for control of unwanted nematodes claim 80 , the method comprising administering to mammals claim 80 , birds claim 80 , or their food claim 80 , plants claim 80 , seeds or soil a composition comprising an effective amount of a compound of .87. The method of wherein the composition comprises a surfactant.88. The method of wherein the composition comprises a co-solvent.89. The method of wherein the composition includes one or more of: a fungicide claim 86 , a ...

Подробнее
22-08-2013 дата публикации

PARASITICIDAL DIHYDROISOXAZOLE COMPOUNDS

Номер: US20130217699A1
Принадлежит: ELI LILLY AND COMPANY

Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. Also provided are compounds and processes useful for making the dihydroisoxazole compounds. 143-. (canceled)46. The compound of claim 44 , or a salt thereof claim 44 , wherein Ris hydrogen and n is 1.50. The compound of claim 44 , or salt thereof claim 44 , being3-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N—((R)-2-oxopyrrolidin-3-yl)-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxamide;N,N-Dimethyl-2-(4-{3-[5-(3,4,5-trichloro-thiophen-2-yl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carbonyl}-piperazin-1-yl)-acetamide;({3-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carbonyl}-amino)-acetic acid methyl ester;({3-[5-(3,4,5-Trichloro-thiophen-2-yl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carbonyl}-amino)-acetic acid methyl ester;3-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(2-oxo-2-(2,2,2-trifluoroethylamino)ethyl)-5,6-dihydro-4H-cyclopenta[c]thiophene-1-carboxamide;3-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carboxylic acid (1,1-dioxo-thietan-3-yl)-amide;3-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-N-(3-oxocyclohexyl)-4,5,6,7-tetrahydrobenzo[c]thiophene-1-carboxamide;3-[5-(3,5-Dichloro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-4,5,6,7-tetrahydro-benzo[c]thiophene-1-carboxylic acid (1,1-dioxo- ...

Подробнее
29-08-2013 дата публикации

COMPOUNDS, COMPOSITIONS, PROCESSES OF MAKING, AND METHODS OF USE RELATED TO INHIBITING MACROPHAGE MIGRATION INHIBITORY FACTOR

Номер: US20130225586A1
Принадлежит: CPSI STOCKHOLDER TRUST

The present invention provides a compound having Formula I or II: 2. The compound of claim 1 , which is a compound having Formula I claim 1 , a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable prodrug thereof.3. The compound of claim 1 , which is a compound having Formula II claim 1 , a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable prodrug thereof.7. The compound of claim 1 , wherein B is oxygen.8. The compound of claim 1 , wherein R and Rare each independently selected from the group consisting of hydrogen claim 1 , (C-C)cycloalkyl claim 1 , (C-C)alkoxy claim 1 , (C-C)alkyl claim 1 , phenyl claim 1 , (C-C)heteroaryl claim 1 , (C-C)heterocyclic and (C-C)cycloalkyl; wherein each of the aforesaid (C-C)alkyl claim 1 , phenyl claim 1 , (C-C)heteroaryl claim 1 , (C-C)heterocyclic and (C-C)cycloalkyl substituents may optionally be substituted by one to four moieties independently selected from the group consisting of halo claim 1 , (C-C)alkyl claim 1 , (C-C)alkenyl claim 1 , (C-C)alkynyl claim 1 , perhalo(C-C)alkyl claim 1 , phenyl claim 1 , (C-C)heteroaryl claim 1 , (C-C)heterocyclic claim 1 , (C-C)cycloalkyl claim 1 , hydroxy claim 1 , (C-C)alkoxy claim 1 , perhalo(C-C)alkoxy claim 1 , phenoxy claim 1 , (C-C)heteroaryl-O— claim 1 , (C-C)heterocyclic-O— claim 1 , (C-C)cycloalkyl-O— claim 1 , (C-C)alkyl-S—; wherein two independently chosen Ralkyl-containing groups may be taken together with any nitrogen atom to which they are attached to form a three to forty membered claim 1 , cyclic heterocyclic or heteroaryl ring.9. The compound of claim 1 , wherein R and Rare each independently selected from the group consisting of hydrogen claim 1 , (C-C)cycloalkyl claim 1 , (C-C)alkoxy claim 1 , (C-C)alkyl claim 1 , phenyl claim 1 , (C-C)heteroaryl claim 1 , (C-C)heterocyclic and (C-C)cycloalkyl; wherein each of the aforesaid (C-C)alkyl claim 1 , phenyl claim 1 , (C-C)heteroaryl claim 1 , (C-C)heterocyclic and (C-C)cycloalkyl ...

Подробнее
29-08-2013 дата публикации

MODIFIED LYSINE-MIMETIC COMPOUNDS

Номер: US20130225644A1
Принадлежит: ZEALAND PHARMA A/S

Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed. 2. The compound according to claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , or prodrug thereof claim 1 , wherein k is 0 or 1.3. The compound according to claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , or prodrug thereof claim 1 , wherein:{'sup': 2', '3, 'Y′ is NRR;'}{'sup': '2', 'Ris H; and'}{'sup': 3', '6', '6, 'sub': '1-10', 'Ris selected from the group consisting of H, an optionally substituted Calkyl, C(O)R, and C(O)OR.'}4. The compound according to claim 3 , or a pharmaceutically acceptable salt claim 3 , ester claim 3 , hydrate claim 3 , or prodrug thereof claim 3 , wherein Ris H.5. The compound according to claim 3 , or a pharmaceutically acceptable salt claim 3 , ester claim 3 , hydrate claim 3 , or prodrug thereof claim 3 , wherein Ris C(O)Rand Ris H or an optionally substituted Calkyl.6. The compound according to claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , or prodrug thereof claim 1 , wherein Y′ is OR.7. The compound according to claim 6 , or a pharmaceutically acceptable salt claim 6 , ester claim 6 , hydrate claim 6 , or prodrug thereof claim 6 , wherein Ris H or an optionally substituted Calkyl.8. The compound according to claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , or prodrug thereof claim 1 , wherein Ris H.9. The compound according to claim 1 , or a pharmaceutically acceptable salt claim 1 , ester claim 1 , hydrate claim 1 , or prodrug thereof claim 1 , wherein:{'sup': '1', 'Ris an amino acid side chain selected from the group consisting of valine, norvaline, leucine, norleucine, isoleucine, methionine, alanine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, lysine, arginine, histidine, aspartic acid, ...

Подробнее
12-09-2013 дата публикации

PYRROLIDINONE CARBOXAMIDE DERIVATIVES

Номер: US20130237514A1
Принадлежит: ChemoCentryx, Inc.

Pyrrolidinone carboxamide compounds are provided that are useful for inhibiting the binding of ligands to the ChemR23 receptor. 3. A compound of claim 1 , wherein Ris methyl.4. A compound of claim 1 , wherein Ris methyl claim 1 , and Ris H or Calkyl.5. A compound of claim 1 , wherein Ris H or Calkyl claim 1 , Ris methyl claim 1 , and Ris H or Calkyl.6. A compound of claim 1 , wherein Ris CF.7. A compound of claim 1 , wherein Ris methyl and Ris CF.9. A compound of claim 8 , wherein Ris selected from the group consisting of —NRRand RRN—Calkyl.10. A compound of claim 9 , wherein Ris RRN—Calkyl.11. A compound of claim 9 , wherein Ris —NRR.12. A compound of claim 8 , wherein Rand Rare each methyl.13. A compound of claim 12 , wherein Ris selected from the group consisting of CF claim 12 , CN and cyclopropyl.14. A compound of claim 8 , wherein Ris mono- or di-(Calkyl)amino-Calkyl claim 8 , and Ris methyl.15. A compound of claim 14 , wherein Ris di(Calkyl)aminomethyl.16. A compound of claim 8 , wherein Rand Rare each methyl.18. A compound of claim 17 , wherein Ris H claim 17 , and Rand Rare each methyl.19. A compound of claim 18 , wherein Ris CF.21. A pharmaceutical composition comprising a compound of and a pharmaceutically acceptable excipient.221111111111111111111111111111111. The pharmaceutical composition of claim 21 , wherein the compound is a compound provided in claim 21 , B claim 21 , C claim 21 , D claim 21 , E claim 21 , F claim 21 , G claim 21 , H claim 21 , I claim 21 , J claim 21 , K claim 21 , L claim 21 , M claim 21 , N claim 21 , O claim 21 , P claim 21 , Q claim 21 , R claim 21 , S claim 21 , T claim 21 , U claim 21 , V claim 21 , W claim 21 , X claim 21 , Y claim 21 , Z claim 21 , AA claim 21 , BB claim 21 , CC claim 21 , DD claim 21 , EE and FF.23. A method of treating a disease or disorder in a mammal claim 1 , said method comprising administering to said subject a therapeutically effective amount of a compound of claim 1 , for a period of time ...

Подробнее
12-09-2013 дата публикации

PYRIDAZINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

Номер: US20130237545A1
Автор: III John A., Lowe
Принадлежит: AGENEBIO, INC.

This invention relates to pyridazine derivatives, compositions comprising therapeutically effective amounts of those pyridazine derivatives and methods of using those derivatives or compositions in treating central nervous system (CNS) disorders with cognitive impairment that are responsive to agonists of α5 subunit containing GABAreceptor, e.g., age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia and cancer-therapy-related cognitive impairment. 4. The compound according to claim 3 , wherein at least one of Rand Ris hydrogen.5. The compound according to claim 4 , wherein Rand Rare each independently hydrogen.6. The compound according to claim 3 , wherein at least one of Rand Ris (C1-C12)-aliphatic- substituted at each substitutable position with 0-3 substituents independently selected from J.7. The compound according to claim 6 , wherein Rand Rare each independently (C1-C12)-aliphatic- substituted at each substitutable position with 0-3 substituents independently selected from J.8. The compound according to claim 7 , wherein Rand Rare each independently unsubstituted (C1-C4)-aliphatic.9. The compound according to claim 8 , wherein Rand Rare each independently methyl claim 8 , ethyl or allyl.10. The compound according to claim 7 , wherein Rand Rare each independently (C1-C4)-alkyl claim 7 , and wherein at least one of Rand Ris substituted with at least one (C6-C10)-aryl.11. The compound according to claim 10 , wherein Rand Rare each independently substituted with at least one (C6-C10)-aryl.12. The compound according to or claim 10 , wherein the at least one (C6-C10)-aryl is phenyl.13. The compound according to claim 6 , wherein Ris H— and Ris (C1-C12)-aliphatic-substituted at each substitutable position with 0-3 substituents independently selected from J.14. The compound according to claim 13 , wherein Ris unsubstituted (C1-C4)-alkyl.15. The compound ...

Подробнее
12-09-2013 дата публикации

INJECTABLE EMULSION OF SEDATIVE HYPNOTIC AGENT

Номер: US20130237548A1
Принадлежит: AstraZeneca AB

Polymorphs of 7-methyl-5-(3-piperazin-1-ylmethyl-[1,2,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2,3-dihydroisoindol-1-one mesylate salt, methods of making these polymorphs and uses thereof. 1. 7-Methyl-5-(3-piperazin-1-ylmethyl-[1 ,2 ,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2 ,3-dihydroisoindol-1-one mesylate salt Polymorph A , which has an XRPD pattern as shown in .4. A pharmaceutical composition comprising 7-methyl-5-(3-piperazin-1-ylmethyl-[1 claim 1 ,2 claim 1 ,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2 claim 1 ,3-dihydroisoindol-1-one mesylate salt claim 1 , Polymorph A claim 1 , according to claim 1 , and at least one pharmaceutically acceptable carrier.5. A method for the treatment of pain in a warm-blooded animal claim 1 , comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of 7-methyl-5-(3-piperazin-1-ylmethyl-[1 claim 1 ,2 claim 1 ,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2 claim 1 ,3-dihydroisoindol-1-one mesylate salt claim 1 , Polymorph A claim 1 , according to .6. A method for the treatment of anxiety in a warm-blooded animal claim 1 , comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of 7-methyl-5-(3-piperazin-1-ylmethyl-[1 claim 1 ,2 claim 1 ,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2 claim 1 ,3-dihydroisoindol-1-one mesylate salt claim 1 , Polymorph A claim 1 , according to .7. A method of making 7-methyl-5-(3-piperazin-1-ylmethyl-[1 claim 1 ,2 claim 1 ,4]oxadiazol-5-yl)-2-(4-trifluoromethoxybenzyl)-2 claim 1 ,3-dihydroisoindol-1-one mesylate salt claim 1 , Polymorph A according to claim 1 , comprising:dissolving 4-{5-[7-methyl-1-oxo-2-(4-trifluoromethoxy-benzyl)-2,3-dihydro-1H-isoindol-5-yl]-[1,2,4]oxadiazol-3-ylmethyl}-piperazine-1-carboxylic acid tert-butyl ester in 10% water/90% 1-butanol with agitation at 85 to 90° C.;slowly adding methanesulfonic acid and stirring and maintaining the mixture at ...

Подробнее
12-09-2013 дата публикации

HETEROCYCLIC COMPOUNDS AS S1P1 AGONISTS FOR THE TREATMENT OF AUTOIMMUNE AND VASCULAR DISEASES

Номер: US20130237566A1
Принадлежит:

Disclosed are compounds of Formula (I) or stereoisomers, salts, or prodrugs thereof, wherein: W is CHor O; Q is Formula (II), Formula (III) or Formula (IV); and R, R, R, R, n, and G are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease. 6. The compound according to or a pharmaceutically acceptable salt thereof claim 1 , wherein said compound is selected from: racemic (3R* claim 1 ,4S*)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-4-ol claim 1 , TFA (1); racemic-2-amino-5-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)-2 claim 1 ,3-dihydro-1H-inden-1-ol claim 1 , TFA salt (2); racemic-2-amino-6-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4-tetrahydronaphthalen-1-ol claim 1 , TFA salt (3); racemic (3R* claim 1 ,4R*)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-4-ol claim 1 , TFA (4); racemic 3-((3R* claim 1 ,4R*)-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-3-ylamino)propanoic acid claim 1 , TFA salt (5); racemic (3R* claim 1 ,4S*)-tert-butyl-4-hydroxy-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-3-ylcarbamate (6 and 7); (3S claim 1 ,4R)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-4-ol claim 1 , TFA salt (8); (3R claim 1 ,4S)-3-amino-7-(5-(3-phenyl-4-(trifluoromethyl)isoxazol-5-yl)-1 claim 1 ,2 claim 1 ,4-oxadiazol-3-yl)chroman-4-ol claim 1 , TFA salt (9 ...

Подробнее
26-09-2013 дата публикации

Substituted piperidines

Номер: US20130252948A1
Принадлежит: Bayer Intellectual Property GmbH

The invention relates to novel substituted piperidines, to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular diseases and tumour diseases. 114-. (canceled)19. The method of claim 15 , wherein the phenyl substituent and the 1 claim 15 ,2 claim 15 ,4-oxadiazol-5-yl substituent of the compound of formula (I) bonded to the piperidine ring are in cis positions to one another.20. The method of claim 15 , wherein the carbon atom to which the phenyl substituent is bonded in the compound of formula (I) is in an S configuration and the carbon atom to which the 1 claim 15 ,2 claim 15 ,4-oxadiazol-5-yl substituent is bonded is also in an S configuration.22. The method of claim 21 , wherein the compound is a cis stereoisomer.23. The method of claim 21 , wherein the compound of formula (I) is {3-(3-Cyclopropyl-1 claim 21 ,2 claim 21 ,4-oxadiazol-5-yl)-5-[4-(trifluoromethoxy)phenyl]piperidin-1-yl}(1 claim 21 ,1-dioxidothiomorpholin-4-yl)methanone [cis isomer] claim 21 , or a salt thereof.24. The method of claim 15 , wherein the compound of formula (I) is administered as a pharmaceutical composition claim 15 , comprising the compound of formula (I) and an inert nontoxic pharmaceutically acceptable excipient.25. The method of claim 15 , wherein the thromboembolic disorder is selected from the group consisting of: ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (non-STEMI) claim 15 , stable angina pectoris claim 15 , unstable angina pectoris claim 15 , reocclusions and restenoses after coronary interventions such as angioplasty claim 15 , stent implantations or aortocoronary bypass claim 15 , peripheral arterial occlusion diseases claim 15 , pulmonary embolisms claim 15 , deep venous thromboses and renal vein thromboses claim 15 , transitory ischaemic ...

Подробнее
03-10-2013 дата публикации

NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES

Номер: US20130261141A1
Принадлежит: Bayer Intellectual Property GmbH

The present application relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which also include arthropods and especially insects. 2. A salt claim 1 , tautomeric and/or isomeric form and N-oxides of the compound of formula (I) according to .3. A composition claim 1 , wherein said composition comprises at least one compound of formula (I) according to .4. A method for controlling pests claim 1 , wherein a compound of the formula (I) according to is allowed to act on the pests and/or their habitat.5. A composition claim 2 , wherein said composition comprises at least one compound of formula (I) according to .6. A method for controlling pests claim 2 , wherein a compound of the formula (I) according to is allowed to act on the pests and/or their habitat.7. A method for controlling pests claim 3 , wherein said composition according to is allowed to act on the pests and/or their habitat. The present invention relates to novel heterocyclic compounds, to processes for preparation thereof and to the use thereof for controlling animal pests, which also include arthropods and especially insects.WO 2008/028903 A2, WO 2003/077918 A1 and WO 2003/029210 A2 disclose heterocyclic compounds for which pharmaceutical applications are described.Further heterocycles which may be used in plant protection are described in WO 2009/149858, WO 2010/006713, WO 2011/045240 and WO 2011/045224.Modern crop protection compositions have to meet many demands, for example in relation to efficacy, persistence and spectrum of their action and possible use. Questions of toxicity, the combinability with other active compounds or formulation auxiliaries play a role, as well as the question of the expense that the synthesis of an active compound requires. Furthermore, resistances may occur. For all these reasons alone, the search for novel crop protection agents cannot be considered as having been concluded, and there is a ...

Подробнее
03-10-2013 дата публикации

1-(HETEROCYCLIC CARBONYL) PIPERIDINES

Номер: US20130261155A1
Принадлежит:

The present invention relates to fungicidal 1-(heterocyclic carbonyl) piperidines and their thiocarbonyl derivatives, their process of preparation and intermediate compounds for their preparation, their use as fungicides, particularly in the form of fungicidal compositions and methods for the control of phytopathogenic fungi of plants using these compounds or their compositions. 3. A compound according to wherein A is selected in the list consisting of A; A; Aand A.4. A compound according to wherein A represents Awherein Rrepresents a substituted or non-substituted C-C-alkyl claim 2 , C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted C-C-alkoxy; Rrepresents a hydrogen atom or a halogen atom and Rrepresents a substituted or non-substituted C-C-alkyl.5. A compound according to wherein A represents Awherein Rrepresents C-C-alkyl claim 2 , C-C-halogenoalkyl comprising up to 3 halogen atoms that can be the same or different; Rrepresents a hydrogen atom; a chlorine atom; or a fluorine atom; and Rrepresents a methyl.6. A compound according to wherein T represents O.7. A compound according to wherein n represents 0 or 1.8. A compound according to wherein Qrepresents a bond or an oxygen atom.9. A compound according to wherein B represents a substituted or non-substituted phenyl ring; a substituted or non-substituted naphthyl ring; a substituted or non-substituted pyridyl ring; a substituted or non-substituted thienyl ring; or a substituted or non-substituted benzothienyl ring.10. A compound according to wherein B represents a substituted or non-substituted phenyl ring11. A compound according to wherein B represents a substituted or non-substituted naphthyl ring.12. A compound according to wherein X independently represents a halogen atom; substituted or non-substituted C-C-alkyl; C-C-halogenoalkyl comprising up to 9 halogen atoms that can be the same or different; substituted or non-substituted C-C-alkoxy or ...

Подробнее
03-10-2013 дата публикации

ONE-POT PROCESS FOR THE SYNTHESIS OF ILOPERIDONE

Номер: US20130261308A1
Принадлежит: PROCOS. S.p.A.

Disclosed is a process for the synthesis of iloperidone starting from 4-hydroxy-3-methoxy acetophenone (acetovanillone), 1-chloro-3-bromo propane and 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole hydrochloride, using a one-pot method. 2. Process according to wherein isolating said iloperidone comprises filtrating the reaction mixture to remove inorganic salts followed by concentrating the reaction mixture.3. Process according to claim 1 , wherein the first and second steps are carried out in an organic solvent or in a mixture of organic solvents independently selected from acetonitrile claim 1 , N claim 1 ,N-dimethylformamide claim 1 , N claim 1 ,N-dimethylacetamide claim 1 , N-methylpyrrolidone or mixtures of acetonitrile with N claim 1 ,N-dimethylformamide.4. Process according to wherein the inorganic base of the first and second steps is independently selected from potassium carbonate claim 1 , potassium bicarbonate claim 1 , sodium carbonate and sodium bicarbonate.5. Process according to wherein in the first step 1 molar equivalent of acetovanillone is added to an organic solution of 0.9-1.2 molar equivalents of 1-bromo-3-chloropropane in the presence of an inorganic base in an amount ranging from 0.9-2.0 molar equivalents claim 1 , at a temperature ranging from 45° C. to the reflux temperature of the reaction mixture.6. Process according to wherein in the second step the inorganic base is used in an amount ranging from 1.0-4.0 molar equivalents with respect to 1 molar equivalent of starting acetovanillone and 6-fluoro-3-(4-piperidinyl)-1 claim 1 ,2-benzisoxazole hydrochloride is used in an amount ranging from 0.85-1.20 molar equivalents with respect to 1 molar equivalent of starting acetovanillone claim 1 , at a temperature ranging from 70° C. to the reflux temperature of the reaction mixture.7. Process according to claim 1 , wherein the first and second steps are carried out in acetonitrile or mixtures of acetonitrile with N claim 1 ,N-dimethylformamide.8. ...

Подробнее
10-10-2013 дата публикации

HETEROARYLS AND USES THEREOF

Номер: US20130267563A1
Принадлежит: Millennium Pharmaceuticals, Inc.

This invention provides compounds of formula IA or IB: wherein HY, R, R, G, W, n, and A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. (canceled)8. (canceled)9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)19. The compound of claim 18 , wherein one of X claim 18 , X claim 18 , or Xis N.20. The compound of claim 18 , wherein all of X claim 18 , X claim 18 , and Xare CR.21. The compound of claim 19 , wherein each occurrence of Ris independently selected from —CN claim 19 , —OR claim 19 , —N(R) claim 19 , halogen claim 19 , Calkyl claim 19 , —N(R)COR claim 19 , or wherein two occurrences of R claim 19 , taken together with the atoms to which they are bound form an optionally substituted group selected from a fused 5- or 6-membered cycloaliphatic claim 19 , 4-10-membered heterocyclyl claim 19 , 6-10-membered aryl or 5-10-membered heteroaryl ring claim 19 , wherein the heterocyclyl and heteroaryl rings have 1-3 heteroatoms independently selected from nitrogen claim 19 , oxygen claim 19 , or sulfur.23. The compound of claim 22 , wherein Xis N claim 22 , Gis —N(R)— claim 22 , and Xand Xare CH.24. The compound of claim 22 , wherein Xand Xare N claim 22 , Gis —N(R)— claim 22 , and Xis CH.25. The compound of claim 22 , wherein Xis N claim 22 , Gis —N(R)— claim 22 , and Xand Xare CH.26. The compound of claim 22 , wherein Xis N claim 22 , Xis CH claim 22 , Xis N(R)— and Gis ═N—.27. The compound of claim 18 , wherein Ring A is an optionally substituted 6-10-membered aryl or 5-10-membered heteroaryl having 1-5 heteroatoms independently selected from nitrogen claim 18 , oxygen claim 18 , or sulfur; and n is 0 to 3.28. The compound of claim 27 , wherein Ring A is a phenyl group optionally ...

Подробнее
17-10-2013 дата публикации

VIOLET LASER EXCITABLE DYES AND THEIR METHOD OF USE

Номер: US20130273569A1
Принадлежит:

The present invention provides dye compounds optimally excited at about 400 nm and have a Stokes shift of at least about 80 nm. These dyes find use in detection of analyte in a sample and the preparation of dye-conjugates. 2. The compound according to claim 1 , wherein Ris alkyl substituted with —OR′ claim 1 , ═O claim 1 , ═NR′ claim 1 , ═N—OR′ claim 1 , —NR′R″ claim 1 , —SR′ claim 1 , -halogen claim 1 , —SiR′R″R′″ claim 1 , —OC(O)R′ claim 1 , —C(O)R′ claim 1 , —COR′ claim 1 , —CONR′R″ claim 1 , —OC(O)NR′R″ claim 1 , —NR″C(O)R′ claim 1 , —NR′—C(O)NR″R′″ claim 1 , —NR″C(O)R′ claim 1 , —NR—C(NR′R″R′″)═NR″″ claim 1 , —NR—C(NR′R″)═NR′″ claim 1 , —S(O)R′ claim 1 , —S(O)R′ claim 1 , —S(O)NR′R″ claim 1 , —NRSOR′ claim 1 , —CN and —NO; wherein R′ claim 1 , R″ claim 1 , R′″ and R″″ each independently are selected from the group consisting of hydrogen claim 1 , substituted or unsubstituted heteroalkyl claim 1 , substituted or unsubstituted aryl claim 1 , substituted or unsubstituted alkyl claim 1 , alkoxy claim 1 , thioalkoxy and arylalkyl.3. The compound according to claim 1 , wherein Ris —(CH)SO—.4. The compound according to claim 1 , wherein X is —CR claim 1 , Y is nitrogen claim 1 , and Z is oxygen.5. The compound according to claim 4 , wherein Ris hydrogen.6. The compound according to claim 1 , wherein Ris —SO—.7. The compound according to claim 1 , wherein Ris alkoxy.8. The compound according to claim 1 , wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Ror Rcomprises a sulfo group.9. (canceled)10. (canceled)11. The compound according to wherein at least one of R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , R claim 1 , Ror Rcomprises a reactive group claim 1 , carrier molecule or solid support.12. The compound according to claim 1 , wherein Ror Rcomprises a reactive group claim 1 , carrier molecule or solid support.13. The compound according to claim 1 , wherein the reactive group ...

Подробнее
17-10-2013 дата публикации

Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Номер: US20130274253A1
Принадлежит: SANOFI SA

The present invention relates to novel chemical compounds derived from pyrimidines, to the method for preparing same, to the novel intermediates obtained, to the use thereof as drugs, to the pharmaceutical compositions containing same, and to the therapeutic use thereof as AKT inhibitors.

Подробнее
17-10-2013 дата публикации

PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS

Номер: US20130274283A1

Premature termination codons readthrough compounds, composition thereof, and methods of making and using the same are provided. 1. A system for high throughput assay for readthrough compound having the ability to read through premature termination codons (PTCs) in RNA , comprising high throughput reading trays and wells containing a plasmid ,wherein the plasmid comprises a fragment of ATM gene that contains a PTC mutation, which fragment being flanked by a sequence that initiates transcription of:a) a myc epitope,b) the ATM fragment, andc) a V5 epitope;wherein the assay is based on a coupled protein transcription/translation (PTT) reaction that is driven by the plasmid;wherein the reading trays are coated with an antibody to the myc epitope; andwherein an antibody to V5 is provided for attaching to readthrough proteins expressing the V5 epitope.2. The system of claim 1 , wherein the V5 epitope is conjugated to horseradish peroxidase.3. The system of claim 1 , further comprising a robot.4. A method of screening for readthrough compounds having the ability to read through premature termination codons (PTCs) in RNA claim 1 , comprising: a) a myc epitope,', 'b) the ATM fragment, and', 'c) a V5 epitope;, 'providing a plasmid template to a reaction well having a test compound to cause a coupled protein transcription/translation (PTT) reaction to occur to generate a PTT reaction product, the plasmid template comprising a fragment of ATM gene that contains a PTC mutation, which fragment being flanked by a sequence that initiates transcription ofadding the PTT reaction product to high throughput reading trays, which are coated with an antibody to the myc epitope to capture a protein fragment of the fragment of ATM gene,adding an antibody to the V5 epitope (V5 antibody) to wells in the reading trays,detecting the attachment of the V5 antibody to proteins in the PTT product, andidentifying the test compound as a readthrough compound if the attachment of the V5 antibody to ...

Подробнее
17-10-2013 дата публикации

Cognition Enhancing Compounds and Compositions, Methods of Making, and Methods of Treating

Номер: US20130274299A1
Принадлежит:

The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions. 312-. (canceled)13. The compound of selected from the group consisting of5-((1R,5R)-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-d3-1,2,4-oxadiazole,5-((1R,5R)-2,2-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1R,5R)-4,4-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1R,5R)-2,2,4,4-d4-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1R,5R)-4,4,5-d3-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1R,5R)-6,6-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1S,5S)-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-d3-1,2,4-oxadiazole,5-((1S,5S)-2,2-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1S,1S)-4,4-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1S,5S)-2,2,4,4-d4-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole,5-((1S,5S)-4,4,5-d3-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole, and5-((1S,5S)-6,6-d2-3-azabicyclo[3.1.0]hexan-1-yl)-3-methyl-1,2,4-oxadiazole.1540-. (canceled)41. A pharmaceutically acceptable composition comprising a compound of and a pharmaceutically acceptable carrier.42. A method comprising administering an effective amount of a compound or composition of to a subject in need thereof.43. The method of claim 42 , wherein the subject is suffering from presenile dementia claim 42 , senile dementia ...

Подробнее
17-10-2013 дата публикации

Arylethynyl Derivatives

Номер: US20130274464A1
Принадлежит:

The present invention relates to ethynyl compounds of formula I

Подробнее
31-10-2013 дата публикации

METHODS FOR USING 1,2,4-OXADIAZOLE BENZOIC ACID COMPOUNDS

Номер: US20130289007A1
Принадлежит: PTC Therapeutics Inc.

Novel 1,2,4-oxadiazole benzoic acid compounds, methods of using and pharmaceutical compositions comprising an 1,2,4-oxadiazole benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith. 120-. (canceled)24. The method of claim 23 , wherein X is halogen.25. The method of claim 24 , wherein X is F.26. The method of claim 23 , wherein Ris hydrogen.27. The method of claim 23 , wherein R claim 23 , R claim 23 , Rand Rare hydrogen.28. The method of claim 23 , wherein R claim 23 , R claim 23 , R claim 23 , Rand Rare hydrogen.29. The method of claim 21 , wherein the compound is: 3-[5-(2-fluoro-phenyl)-[1 claim 21 ,2 claim 21 ,4]oxadiazol-3-yl]-benzoic acid or a pharmaceutically acceptable salt thereof.30. The method of claim 29 , wherein the patient has undergone a screening process to determine the presence of a nonsense mutation.31. The method of claim 29 , wherein the patient is a human.32. The method of claim 29 , wherein the compound is administered parenterally claim 29 , transdermally claim 29 , mucosally claim 29 , nasally claim 29 , buccally claim 29 , sublingually claim 29 , or orally.33. The method of claim 32 , wherein the compound is administered orally in a powder claim 32 , granule or suspension form.34. The method of claim 29 , wherein the therapeutically effective amount is from about 1 mg to about 2000 mg per day.35. The method of claim 29 , wherein the disease or disorder is a muscular dystrophy.36. The method of claim 35 , wherein the muscular dystrophy is Duchenne muscular dystrophy.37. The method of claim 29 , wherein the disease or disorder is cystic fibrosis.38. A method for increasing the expression of functional dystrophin protein in a patient having a muscular dystrophy claim 29 , comprising administering an effective amount of 3-[5-(2-fluoro-phenyl)-[1 ...

Подробнее
31-10-2013 дата публикации

HETEROARYLTHIO DERIVATIVES AND ANALOGUES

Номер: US20130289047A1
Автор: Fick David, Helton David
Принадлежит: EPIOMED THERAPEUTICS, INC.

Heteroarylthio compounds covalently linked to an arylpiperazine moiety for the treatment of neurological conditions. 7. The heteroarylthio compound of claim 1 , wherein m is selected from the group consisting of 2 claim 1 , 3 claim 1 , and 4.8. The heteroarylthio compound of claim 1 , wherein L is substituted with alkyl groups.14. The heteroarylthio compound of claim 1 , wherein the compound is selected from the group consisting of:1-{2-[(1-methyl-1H-imidazol-2-yl)thio]ethyl}-4-[3-(trifluoromethyl)phenyl]piperazine;1-[2-(5-pyridin-4-yl-[1,3,4]oxadiazol-2-ylsulfanyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine;1-{3-[(1-methyl-1H-imidazol-2-yl)thio]propyl}-4-[3-chlorophenyl]piperazine;1-[3-(1-phenyl-1H-tetrazol-5-ylsulfanyl)propyl]-4-(3-chlorophenyl)piperazine; and1-[2-(5-pyridin-4-yl-[1,3,4]oxadiazol-2-ylsulfanyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine.1518-. (canceled)19. The heteroarylthio compound of claim 1 , wherein the compound is selected from the group consisting of:4-{4-[3-(1-methyl-1H-imidazol-2-ylsulfanyl)propyl]piperazin-1-yl}furo[3,2-c]pyridine;4-{4-[3-(1-phenyl-1H-tetrazol-5-ylsulfanyl)propyl]piperazin-1-yl}furo[3,2-c]pyridine; and4-{4-[3-(5-pyridin-4-yl-[1,3,4]oxadiazol-2-sulfanyl)propyl]piperazin-1-yl}furo[3,2-c]pyridine.2021-. (canceled)22. A pharmaceutical composition comprising the heteroarylthio compound of and one or more pharmaceutically acceptable excipients.23. A method of treating a neurological condition claim 1 , comprising the step of administering the heteroarylthio compound of to a subject in need thereof.24. (canceled) This patent application claims the benefit of priority from U.S. Patent Application No. 61/393,349, filed on Oct. 14, 2010 and entitled HETEROARYLTHIO DERIVATIVES AND ANALOGUES. The disclosure of this application is hereby incorporated by reference herein in its entirety.The serotonin receptors, also known as 5-hydroxytryptamine receptors or 5-HT receptors, are a group of G protein-coupled receptors (GPCRs) and ...

Подробнее
07-11-2013 дата публикации

Aryl Substituted Indoles and Their Use as Blockers of Sodium Channels

Номер: US20130296281A1
Принадлежит: Purdue Pharma L.P.

The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R, and Z-Zare defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain. 2. The compound of claim 1 , wherein Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.3. The compound of claim 1 , wherein Zis CR claim 1 , Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.4. The compound of claim 1 , wherein Zis CR claim 1 , Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.5. The compound of claim 1 , wherein Zis CR claim 1 , Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.6. The compound of claim 1 , wherein Zis CR claim 1 , Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.7. The compound of claim 1 , wherein Zis CR claim 1 , Ris A claim 1 , and at least one of Z claim 1 , Z claim 1 , Z claim 1 , and Zis N.8. The compound of with the proviso that when Zis N claim 1 , Z claim 1 , Z claim 1 , Z claim 1 , and Zare CR claim 1 , CR claim 1 , CR claim 1 , and CR claim 1 , respectively claim 1 , G is G claim 1 , wherein r is 0 claim 1 , and Ais optionally substituted heteroaryl claim 1 , then Ris not A.10. The compound of with the proviso that when Z claim 1 , Z claim 1 , Z claim 1 , Z claim 1 , and Zare CR claim 1 , CR claim 1 , CR claim 1 , CR claim 1 , and CR claim 1 , respectively claim 1 , R claim 1 , R claim 1 , and Rare hydrogen claim 1 , Ris A claim 1 , G is G claim 1 , wherein Rand Rare H and Ris haloalkylcarbonyl or optionally substituted arylcarbonyl claim 1 , then Ris other than alkoxycarbonyl.23. The compound of claim 1 , wherein G is G.24. ...

Подробнее
07-11-2013 дата публикации

1H-QUINAZOLINE-2,4-DIONES

Номер: US20130296332A1
Принадлежит:

The present invention relates to 1H-Quinazoline-2,4-diones of formula (I) 2. Compounds according to claim 1 , wherein{'sup': '1', 'sub': '3', 'Rrepresents CFor iso-Propyl and'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents (C-C)alkyl substituted by one to three substituents, the substituents being selected from the group consisting of halogen, nitro, cyano, HCO, (C-C)alkylcarbonyl, hydroxy, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, acylamino, (C-C)alkoxycarbonylamino, except trifluoromethyl or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents heterocyclyl(C-C)alkyl substituted by one to three substituents, the substituents being selected from the group consisting of halogen, nitro, cyano, hydroxy, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, (C-C)alkoxycarbonylamino and the heterocyclyl consist of 3 to 11 ring atoms of which 1-3 ring atoms are hetero atoms or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents phenyl substituted by one to three substituents, the substituents being selected from the group consisting of cyano, hydroxy, alkanediyl, alkenediyl, (C-C)alkoxy, (C-C)alkylcarbonyloxy, (C-C)alkoxycarbonyloxy, amino, (C-C)alkylamino, di(C-C)alkylamino, (C-C)alkoxycarbonylamino or'}{'sup': '2', 'sub': 1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4', '1', '4, 'Rrepresents heterocyclyl optionally substituted by one to three substituents, the substituents being selected from the group consisting of halogen, hydroxy, amino, nitro, cyano, (C-C)alkyl, hydroxy(C-C)alkyl, (C-C)alkoxyalkyl, amino(C-C)alkyl, (C-C)alkylamino(C-C)alkyl, di(C-C)alkylamino(C-C)alkyl, HCO, (C-C)alkylcarbonyl, (C-C)alkoxy, acyloxy, (C-C) ...

Подробнее
07-11-2013 дата публикации

OPTICAL ISOMERS OF AN ILOPERIDONE METABOLITE

Номер: US20130296366A1
Принадлежит:

The present invention relates to novel isomers of a metabolite of Iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them. 1. A pharmaceutical composition comprising (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl]-ethanol or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier or diluent.2. A method for treating a psychotic disorder in a human subject in need of such treatment , the method comprising administering to the subject a therapeutically effective amount of (S)-1-(4-{3-[4-(6-fluoro-benzo[d]isoxazol-3-yl)-piperidin-1-yl]propoxy}-3-methoxy-phenyl]-ethanol or a pharmaceutically acceptable salt thereof.3. The method of claim 2 , wherein the psychotic disorder is schizophrenia or bipolar disorder. This application is a continuation of co-pending U.S. patent application Ser. No. 12/403,755, filed 13 Mar. 2009, which in turn is a continuation of U.S. patent application Ser. No. 10/488,128, filed 16 Sep. 2004, each of which is hereby incorporated herein.The present invention relates to novel isomers of a metabolite of iloperidone, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.More particularly, the invention relates to optical isomers of the metabolite P88-8991 of iloperidone.Iloperidone is an atypical antipsychotic developed for the treatment of schizophrenia, having functional affinity for noradrenergic, dopaminergic and serotoninergic receptors. See for example Richelson E. and Souder T., Life Sciences, 68:29-39 (2000).P-88-8991 is a major circulating metabolite of iloperidone in human plasma, having the formula ASee for example Mutlib A E et al., Drug Metab. Dispos; 23(9):951-964 (1995). P-88-8991 has been shown to have plasma levels in human about 1.5 fold higher than the parent drug. It is roughly as active as iloperidone.P-88-8991 consists Of a mixture of two enantiomers which have never been ...

Подробнее
07-11-2013 дата публикации

ISOXAZOLE DERIVATIVES FOR USE AS FUNGICIDES

Номер: US20130296381A1
Принадлежит:

The present invention relates to isoxazole compounds of formula (I) having fungicidal activity, to agricultural compositions comprising them, and to the use of said compounds and compositions in agriculture for the control of microbial pests, particularly fungal pests, on plants

Подробнее
14-11-2013 дата публикации

2-METHOXY-PYRIDIN-4-YL-DERIVATIVES

Номер: US20130303514A1
Принадлежит: ACTELION PHARMACEUTICALS LTD.

The invention relates to pyridine derivatives of Formula (I) 2. A compound according to claim 1 , wherein the stereocenter of the Rgroups 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy claim 1 , 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy claim 1 , —O—CHCH(OH)—CHNH—CHCOOH claim 1 , —OCHCH(OH)—CHNH—CHCHCOOH claim 1 , —OCHCH(OH)—CHN(CH)—CHCOOH claim 1 , —OCHCH(OH)—CHN(CH)—CHCHCOOH claim 1 , 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy claim 1 , —OCH—(CH)—NH—CHCH(OH)—CHOH claim 1 , —OCHCH(OH)—CHNH—CHCHOH claim 1 , —OCHCH(OH)—CHNH—CH(CHOH) claim 1 , and —OCHCH(OH)—CHNH—CO—(CH)COOH is in the S-configuration claim 1 , or a salt of such compound.3. A compound according to claim 1 , wherein the stereocenter of the Rgroups 2-[(pyrrolidin-3-carboxylic acid)-1-yl]-ethoxy claim 1 , 3-[(pyrrolidin-3-carboxylic acid)-1-yl]-propoxy claim 1 , —O—CHCH(OH)—CHNH—CHCOOH claim 1 , —OCHCH(OH)—CHNH—CHCHCOOH claim 1 , —OCHCH(OH)—CHN(CH)—CHCOOH claim 1 , —OCHCH(OH)—CHN(CH)—CHCHCOOH claim 1 , 3-[(azetidine-3-carboxylic acid)-1-yl]-2-hydroxy-propoxy claim 1 , —OCH—(CH)—NH—CHCH(OH)—CHOH claim 1 , —OCHCH(OH)—CHNH—CHCHOH claim 1 , —OCHCH(OH)—CHNH—CH(CHOH) claim 1 , and —OCHCH(OH)—CHNH—CO—(CH)COOH is in the R-configuration claim 1 , or a salt of such compound.7. A compound according to claim 1 , wherein Rrepresents methyl claim 1 , and Rrepresents ethyl or chloro claim 1 , or a salt of such compound.8. A compound according to claim 1 , wherein Rrepresents methyl claim 1 , and Rrepresents ethyl claim 1 , or a salt of such compound.9. A compound according to claim 1 , wherein Rrepresents methoxy claim 1 , and Rrepresents chloro claim 1 , or a salt of such compound.10. A compound according to claim 1 , wherein Rrepresents —OCHCOOH claim 1 , —OCHCHCHCOOH claim 1 , —OCHCONHCHCHOH claim 1 , —OCHCHCHCONHCHCHOH claim 1 , —OCH—(CH)—NH—(CH)—COOH claim 1 , —OCH—(CH)—N(CH)—(CH)—COOH claim 1 , 2-[(azetidine-3-carboxylic acid)-1-yl]-ethoxy claim 1 , 2-[(pyrrolidin-3-carboxylic acid)-1-yl]- ...

Подробнее
14-11-2013 дата публикации

INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1

Номер: US20130303522A1
Принадлежит: LABORATORIOS SALVAT, S.A.

The compounds of formula (I) are derived from perhydroquinoline and perhydroisoquinoline and are useful as active pharmaceutical ingredients for the prophylaxis or treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1) enzyme-associated disorders, such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration. 2. The method according to claim 1 , wherein in the compound Y is CO or SO.3. The method according to claim 1 , wherein in the compound W1 and W2 is each independently selected from the group consisting of a bond claim 1 , S and NR1.4. The method according to claim 3 , wherein in the compound R1 is H5. The method according to claim 1 , wherein in the compound V is —CO-T claim 1 , —CS-T or —SO-T.7. The method according to claim 1 , wherein in the compound T is NR2R3 claim 1 , R2 claim 1 , OR2 or SR2.8. The method according to claim 1 , wherein in the compound R2 and R3 is each independently selected from the group consisting of H claim 1 , COR4 claim 1 , SOR4 claim 1 , Calkyl claim 1 , phenyl claim 1 , naphthyl claim 1 , benzyl claim 1 , phenethyl claim 1 , Calkenyl claim 1 , Ccycloalkyl claim 1 , and heterocycle claim 1 , particularly claim 1 , 2-furanyl claim 1 , 2-thiophenyl claim 1 , 2-(1-methylindole) claim 1 , quinoline claim 1 , isoquinoline and 2-benzofuranyl.9. The method according to claim 8 , wherein in the compound R2 and R3 is each independently selected from the groups consisting of Calkyl and Calkenyl.10. The method according to claim 9 , wherein in the compound R2 or R3 are optionally substituted with one or several substituents independently selected from the groups consisting of F claim 9 , OR4 claim 9 , NR4R5 claim 9 , COOR4 claim 9 , CONR4R5 claim 9 , phenyl claim 9 , Ccycloalkyl claim 9 , hexenyl claim 9 , ...

Подробнее
21-11-2013 дата публикации

Methods including latent 1,3-dipole-functional compounds and materials prepared thereby

Номер: US20130310570A1

Methods that include latent 1,3-dipole-functional compounds are disclosed herein. The latent 1,3-dipole-functional compound (e.g., an oxime) can be used to form an active 1,3-dipole-functional compound (e.g., a nitrile oxide) that can be used to react with a cyclic alkyne in a dipolar cycloaddition reaction.

Подробнее
28-11-2013 дата публикации

METHOD FOR PRODUCING MALEATE USING WET CRYSTAL

Номер: US20130317214A1
Автор: Tsubuki Takeshi
Принадлежит: Kyorin Pharmaceutical Co., Ltd.

[Problem] To efficiently (without carrying out column purification) provide a high-purity maleate having excellent storage stability, solubility, crystallinity and ease of handling according to the present invention. 2. The method for producing a crystal of a maleate represented by the formula (1) according to claim 1 , wherein the crystal of the compound represented by the formula (2) is dried and then dissolved in the solvent to prepare the solution of the compound represented by the formula (2) claim 1 , andthe crystal of the compound represented by the formula (2) is dried under reduced pressure, or dried by dissolving the crystal in a solvent capable of separating from water into two layers, removing separated water, and concentrating the solution.6. The method for producing a crystal of a maleate represented by the formula (1) according to claim 5 , wherein the crystal of the compound represented by the formula (2) is dried and then dissolved in the solvent to prepare the solution of the compound represented by the formula (2) claim 5 , andthe crystal of the compound represented by the formula (2) is dried under reduced pressure or dried by dissolving the crystal in a solvent capable of separating from water into two layers, removing separated water, and concentrating the solution.8. The method for producing a crystal of a maleate represented by the formula (1) according to claim 7 , wherein the crystal of the compound represented by the formula (2) is dried and then dissolved in the solvent to prepare the solution of the compound represented by the formula (2) claim 7 , andthe crystal of the compound represented by the formula (2) is dried under reduced pressure or dried by dissolving the crystal in a solvent capable of separating from water into two layers, removing separated water, and concentrating the solution. The present invention relates to a method for producing a maleate using a wet crystal of a benz[d][1,3]oxazine derivative.Human neutrophil ...

Подробнее
28-11-2013 дата публикации

Stable synthetic intermediate and method for manufacturing same

Номер: US20130317215A1
Принадлежит: Kyorin Pharmaceutical Co Ltd

[Problem] To provide a stable industrially-manufactured intermediate, enabling an industrially stable supply of 2-pyridyl-benz[d][1,3]oxazine to be provided. [Solution] The compound represented by formula (6) (wherein M represents sodium or potassium).

Подробнее
28-11-2013 дата публикации

Slow Release of Organoboronic Acids in Cross-Coupling Reactions

Номер: US20130317223A1

A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: 1. A method of performing a chemical reaction , comprising:reacting in a reaction mixturea compound selected from the group consisting of an organohalide and an organo-pseudohalide, and {'br': None, 'sup': '1', 'R—B-T\u2003\u2003(I),'}, 'a protected organoboronic acid represented by formula (I) [{'sup': '1', 'Rrepresents an organic group,'}, 'T represents a conformationally rigid protecting group,', {'sup': '3', 'B represents boron having sphybridization,'}, 'a corresponding unprotected organoboronic acid is unstable by the boronic acid neat stability test, and', {'sub': 'B', 'the reaction mixture further comprises a base having a pKof at least 1, and a palladium catalyst; and'}], 'where'}forming a cross-coupled product in the reaction mixture.2. The method of claim 1 , where Rcomprises a 2-heterocyclic group.3. The method of claim 2 , where Ris selected from the group consisting of a 2-furyl group claim 2 , a 2-benzofuryl group claim 2 , a 2-thiophenyl group claim 2 , a 4-(4′-methylthiophene)-thiophenyl group claim 2 , a 2-(N-butoxycarbonyl-pyrollyl) group claim 2 , and a 2-(N-phenylsulfonate-indolyl) group.4. The method of claim 1 , where Rcomprises a vinyl group.5. The method of claim 1 , where Rcomprises a cyclopropyl group.6. The method of claim 1 , where{'sup': '1', 'claim-text': {'br': None, 'sup': 2', '3, 'sub': 'm', 'Y—R—(R)—\u2003\u2003(III),'}, 'Ris a group represented by formula (III)where Y represents a halogen group or a pseudohalogen group;{'sup': '2', 'Rrepresents an aryl group;'}{'sup': '3', 'Rcomprises at least one group selected from the group consisting of an alkyl group, a heteroalkyl group, an alkenyl group, a heteroalkenyl group, an alkynyl group, a heteroalkynyl group, an aryl group, and a heteroaryl group; ...

Подробнее
12-12-2013 дата публикации

DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF

Номер: US20130331377A1
Принадлежит: YUHAN CORPORATION

The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HTreceptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony. 2. The method of claim 1 , wherein{'sub': 1', '1-5', '1-5', '2-6', '2-6', '1-5', '1-5', '1-5', '1-5', '1-5', '1-5', '1-5', '1-5, 'Ris a phenyl group substituted with one or more substituents selected from the group consisting of hydroxy, amino, halogen, cyano, nitro, hydroxycarbonyl, Calkyl (where the Calkyl is optionally substituted with halogen or amino), Calkenyl, Calkynyl, Calkoxy (where the Calkoxy is optionally substituted with halogen), Calkylthio, mono- or di-Calkylamino, Calkylsulfonylamino, Calkylcarbonylamino, Calkoxycarbonyl, aminosulfonyl, aminocarbonyl, Calkylaminocarbonyl, and benzyloxycarbonylamino; or'}{'sub': 1-5', '1-5', '1-5', '1-5', '1-5', '1-5, 'a heteroaryl group selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, imidazolyl, pyrazolyl, triazolyl, oxazolyl, thiazolyl, furanyl, pyrrolyl, thiophenyl, naphthyl, indanyl, quinolinyl, quinolinonyl, chromenonyl, dihydroindolonyl, isoindoline-1,3-dionyl, dihydrobenzimidazolonyl, benzoxazolonyl, benzofuranyl, benzothiophenyl, benzo[d][1,3]dioxolyl, dihydrobenzo[1,4]dioxinyl, indolyl, indolinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, and indazolyl, wherein the heteroaryl group may be optionally substituted with one or more substituents selected from the group ...

Подробнее
12-12-2013 дата публикации

PROCESS FOR THE PREPARATION OF AN OREXIN RECEPTOR ANTAGONIST

Номер: US20130331379A1
Принадлежит:

The present invention is directed to processes for preparing a diazepane compound which is an antagonist of orexin receptors, and which is useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is further directed to crystalline forms of this diazepane compound and pharmaceutical compositions thereof. 2. The process of wherein the activating agent is selected from oxalyl chloride claim 1 , thionyl chloride claim 1 , POCl claim 1 , pivaloyl chloride claim 1 , benzyl chloroformate claim 1 , CDI claim 1 , EDC claim 1 , DCC claim 1 , HOBt claim 1 , HOAt claim 1 , T3P claim 1 , and HAUT.3. The process of wherein the weak base is selected from triethylamine claim 1 , diisopropylethylamine claim 1 , tributylamine claim 1 , dicyclohexylmethylamine claim 1 , N claim 1 ,N-dimethylaniline claim 1 , diazabicyclononane claim 1 , 1 claim 1 ,2 claim 1 ,2 claim 1 ,6 claim 1 ,6-pentamethylpiperidine claim 1 , diisopropylamine claim 1 , 1 claim 1 ,8-diazabicyclo[5.4.0]undec-7-ene claim 1 , tetramethylguanidine claim 1 , pyridine claim 1 , 2 claim 1 ,6-lutidine claim 1 , N-methylmorpholine claim 1 , and N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylene diamine claim 1 , KHCO claim 1 , NaHCO claim 1 , CsCO claim 1 , K(CO) claim 1 , Na(CO) claim 1 , NaOH claim 1 , KOH claim 1 , and a phosphate base.4. The process of wherein the step of contacting the compound of the formula II with an activating agent to form an acid chloride is conducted in an organic solvent selected from: dichloromethane claim 1 , isopropyl acetate claim 1 , acetonitrile claim 1 , ethyl acetate claim 1 , tetrahydrofuran claim 1 , methyl-tetrahydrofuran claim 1 , toluene claim 1 , methyl acetate claim 1 , and methyl tert-butyl ether.5. The process of wherein the step of contacting the compound of the formula II with an activating agent to form an acid chloride is conducted in an amide solvent selected from the ...

Подробнее
12-12-2013 дата публикации

DOSAGE REGIMEN FOR COMT INHIBITORS

Номер: US20130331416A1
Принадлежит: BIAL - PORTELA & CA, S.A.

The invention relates to the use of an oxodiazolyl compound (I) for the preparation of a medicament for the prevention or treatment of central and peripheral nervous system associated disorders, wherein said medicament is administered according to a dosing regimen having a dosing periodicity ranging from about twice a day to about once every other day. 2. An individual dosage unit as claimed in 1 , wherein the compound of general formula I is 5-[3-(2 ,5-dichloro-4 ,6-dimethyl-1-oxy-pyridin-3-yl)-[1 ,2 ,4]-oxadiazol-5-yl]-3-nitrobenzene-1 ,2-diol.3. An individual dosage unit as claimed in which comprises 2 to 300 mg of the to compound of formula I or a pharmaceutically acceptable salt thereof.4. An individual dosage unit as claimed in which comprises 3 to 100 mg of the compound of the formula I or a pharmaceutically acceptable salt thereof.5. An individual dosage unit as claimed in which comprises 5 to 50 mg of the compound of the formula I or a pharmaceutically acceptable salt thereof.6. An individual dosage unit as claimed in in combination with L-DOPA and/or an aromatic L-amino acid decarboxylase inhibitor.7. An individual dosage unit as claimed in in combination with L-DOPA and/or an aromatic L-amino acid decarboxylase inhibitor.8. Method of treating at least one condition or disease in a patient in need thereof comprising administering to the patient an individual dosage unit according to .9. Method of treating at least one condition or disease in a patient in need thereof comprising administering to the patient about twice every day to about once every other day a pharmacologically effective dose of a compound of formula I as defined in .10. Method as claimed in claim 9 , wherein the administration is once daily.11. Method as claimed in claim 9 , wherein the administration is twice daily.12. Method as claimed in claim 9 , wherein the administration is once every other day.13. Method as claimed in claim 9 , wherein the administration is in the morning claim 9 , ...

Подробнее
12-12-2013 дата публикации

MINERALOCORTICOID RECEPTOR ANTAGONISTS

Номер: US20130331419A1
Принадлежит:

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 3. The compound of wherein Ris H.8. The compound of which is(R)—N-{1-[(2R)-2-(4-chlorophenyl)-1-hydroxybutan-2-yl]-1H-indol-4-yl}methanesulfonamide;N-(1-(1-(4-chlorophenyl)-1-(2-cyanocyclopropyl)propyl)-1H-indazol-4-yl)methanesulfonamide;N-(1-(1-(4-chlorophenyl)-1-(3-ethyl-1,2,4-oxadiazol-5-yl)propyl)-1H-indol-4-yl)methanesulfonamide;N-(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)-1H-indazol-4-yl)methanesulfonamide;N-(1-(1-(4-chlorophenyl)-1-(1-hydroxycyclopropyl)propyl)-1H-indol-4-yl)methanesulfonamide;N-(1-(3-(4-chlorophenyl)-2-hydroxypentan-3-yl)-6-fluoro-1H-indol-4-yl)methanesulfonamide;N-(1-(2-(4-chlorophenyl)-1-hydroxybutan-2-yl)indolin-4-yl)methanesulfonamide;N-{1-[3-(4-chlorophenyl)-2-hydroxypentan-3-yl]-1H-indazol-4-ylmethanesulfonamide;N-(1-(2-amino-3-(4-chlorophenyl)pentan-3-yl)-1H-indol-4-yl)methanesulfonamide;1-(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-1H-indazol-4-yl)-3-methyl-sulfonylurea;methyl {4-[(methylsulfonyl)amino]-1H-indol-1-yl}(phenyl)acetate;N-(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-6-fluoro-1H-indol-4-yl)methane sulfonamide;N-(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-1H-indol-4-yl)methanesulfonamide;N-(1-(3-(4-chlorophenyl)-2-hydroxy-2-methylpentan-3-yl)-1H-indazol-4-yl)methanesulfonamide;N-(1-(2-hydroxy-2-methyl-3-(4-(trifluoromethyl)phenyl)pentan-3-yl)-1H-indazol-4-yl)methanesulfonamide;N-(1-(2-(4-chlorophenyl)-1-methoxybutan-2-yl)-1H-indol-4-yl)methanesulfonamide;N-(1-(3-(4-chlorophenyl)-2-oxopentan-3-yl)-1H-indazol-4-yl)methanesulfonamide;N-(1-(2-hydroxy-3-(4-( ...

Подробнее